Die gegenseitige Beeinflussung synthetischer Expressionskassetten in definierten chromosomalen Abschnitten by Spencer, Shawal
 
 
 
Crosstalk of synthetic cassettes in defined chromosomal sites 
 
Von der Fakultät für Lebenswissenschaften 
 
der Technischen Universität Carolo-Wilhelmina 
 
zu Braunschweig 
 
zur Erlangung des Grades eines 
 
Doktors der Naturwissenschaften 
 
(Dr. rer. nat.) 
  
genehmigte 
 
D i s s e r t a t i o n 
 
 
 
 
 
 
 
 
 
 
 
 
von Shawal Spencer 
aus Jagadhri, India 
 
 
 
 
 Druckjahr 2014
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Referent:  Prof. Dr. Reinhard Köster 
2. Referent:  Prof. Dr. Michael Rehli 
 
eingereicht am: 26.05.2014 
mündliche Prüfung (Disputation) am: 23.07.2014 
 
 
Vorveröffentlichungen der Dissertation  
 
Teilergebnisse aus dieser Arbeit wurden mit Genehmigung der Fakultät für  
Lebenswissenschaften, vertreten durch den Mentor der Arbeit, in folgenden Beiträgen vorab  
veröffentlicht:  
 
Publikationen  
Kruse, N., Spencer, S., Wirth, D. . (in press (2014)) In Hauser, H., Wagner, R. (ed.), Animal 
Cell Biotechnology in Biologics Production. DeGruyter, Berlin 
 
Tagungsbeiträge 
 
Spencer, S.: Crosstalk of synthetic cassettes in defined chromosomal sites- An Epigenetics 
Perspective (Oral presentation). COST conference: Epigenetic: From Bench to Bedside 
Athens, Greece (2014). 
 
Spencer, S.: Crosstalk of synthetic cassettes in defined chromosomal sites- An Epigenetics 
Perspective (Oral presentation). Progress Seminar, Helmholtz Centre for Infection Research, 
Braunschweig (2014).  
 
Spencer, S, Zha L,:Towards An HCV mouse model: Overcoming Epigenetic Roadblock(Joint 
oral presentation). 4th Public retreat of the HZI Graduate School, Hahnenklee (2013). 
 
Spencer S.: Crosstalk between synthetic cassettes in a defined chromosomal site(Oral 
presentation). ESACT Conference, Lille, France (2013). 
 
Spencer, S, Natascha Kruse, Hansjörg Hauser and Dagmar Wirth: Crosstalk between 
synthetic cassettes in a defined chromosomal sitePoster presentation). 3rd Public retreat of 
the HZI Graduate School, Bad Bevensen (2012). 
 
Spencer,S.: Crosstalk of synthetic cassettes in defined chromosomal sites(Oral presentation). 
Progress Seminar, Helmholtz Centre for Infection Research, Braunschweig (2012).  
  
 
Acknowledgement 
 
I would like to thank Dr. Dagmar Wirth for accepting me as a PhD student in her department 
and for her honest and generous support during all these years. She kept patience and 
calmness all the time and under her leadership I had the chance to learn many new things.  I 
would like to thank Prof. Dr. Reinhard Koester for accepting to supervise and review my 
thesis. I am very grateful to Prof. Dr. Michael Rehli for his enthusiasm, his continuous 
support and advice, for accommodating me briefly in his lab and his lab members who made 
my short stay in Regensburg a thoroughly enjoyable one. I am also grateful to Dr. 
Hansjörg Hauser. He was always willing to listen to my problems and was very supportive 
throughout. I would like to thank my Grad school for their continuous support and 
enjoyable retreats.  
I would like to thank everybody in MSYS for the wonderful atmosphere, their patience and 
support. In addition, I would like to take the opportunity to thank our closely connected co-
workinggroup – the RDIF department and EXIM colleagues. We not only shared room and 
working material, I also appreciated our combined seminars, brainstorming where I got a 
chance to learn and widen the span of my knowledge. I also would like to thank the whole 
sequencing department and also a special thanks to Maria and Lothar for their technical 
support in difficult FACs sorts and analysis. 
Special thanks to Dr. Natascha Kruse for her precious organization skills and help in the 
various difficult situations (on numerous occasions). Thanks to Sara for her technical and 
moral supportespecially when it came to ordering mice. 
I would also like to thank all former lab members whose support made the journey a 
memorable one: Dr. Daniel Maeda, Dr. Kristina Nehlsen, Agustina Gugliotta, Petra Voeller, 
and Sabrina Herman. I would also like to thank all other friends not personally mentioned 
yet who helped to make my stay in Braunschweig fun and memorable one. 
Last but not least, I would like to thank my parents and my younger sister. Their support, 
motivation and love helped me first to start this journey and then to make it all the way 
until the end. Without their help I would never have had the chance to start and finish my 
study, to work in and explore Germany for over three years and to perform the present 
thesis. I really appreciate their never-ending love, help, support and patience. 
 
  
 
Table of Contents 
 
ABSTRACT .......................................................................................................................................................... 
ZUSAMMENFASSUNG ........................................................................................................................................ 
1 Introduction .................................................................................................................................................. 1 
1.1 Epigenetic role play in gene expression ....................................................................................................... 1 
1.2 DNA methylation .......................................................................................................................................... 4 
1.2.1 Role of DNA methylation in healthy cells, in transcriptional regulation and in cancerous cells ........... 6 
1.3 Histone mediated gene modulation ............................................................................................................ 8 
1.3.1 Crosstalk between histone modifications and transcriptional regulation ........................................ 9 
1.3.2 Histone code hypothesis ...................................................................................................................... 10 
1.3.3 Crosstalk between DNA methylation and histone modification ......................................................... 10 
1.3.4 Histone deacetylases and their inhibitors ........................................................................................... 11 
1.3.5 Action of Valproic acid (VPA) and sodium butyrate ............................................................................ 12 
1.4 Transgene silencing and Position effect ..................................................................................................... 12 
1.5 The CMV and the Tetracycline inducible promoter elements ................................................................... 13 
1.5.1 CMV promoter ..................................................................................................................................... 13 
1.5.2 Synthetic Inducible promoter (Tetracycline inducible promoter) ....................................................... 13 
1.5.3 Utility of inducible promoter system (Tet system) .............................................................................. 15 
1.5.4 Optimization of Tet promoter ............................................................................................................. 15 
1.6 Transgene integration sites within the chromosome ................................................................................ 16 
1.6.1 A well known integration site: the Rosa26 locus ............................................................................ 16 
1.7 Targeted integration through recombinase mediated cassette exchange (RMCE) ................................... 18 
1.7.1 Recombinase mediated cassette exchange (RMCE) ....................................................................... 19 
1.8 Aim of the study ................................................................................................................................................ 22 
2 MATERIAL AND METHODS .......................................................................................................................... 23 
2.1 Materials ............................................................................................................................................................ 23 
2.1.1 Equipment ........................................................................................................................................... 23 
  
 
2.1.2 Consumables........................................................................................................................................ 24 
2.1.3 Chemicals & Kits .................................................................................................................................. 25 
2.2 METHODS .......................................................................................................................................................... 26 
2.2.1 Agarose gel electrophoresis ................................................................................................................ 26 
2.2.2 Restriction analysis .............................................................................................................................. 26 
2.2.3 Mammalian cell culture and mice ....................................................................................................... 26 
2.2.4 Lentiviral gene transfer ........................................................................................................................ 28 
2.2.5 Recombinase mediated cassette exchange (RMCE) ............................................................................ 28 
2.2.6 Chemical treatments ........................................................................................................................... 29 
2.2.7 Flow cytometry .................................................................................................................................... 30 
2.2.8 Chromatin Immunoprecipitation (ChIP) .............................................................................................. 30 
2.2.9 Bisulfite Sequencing ............................................................................................................................. 31 
2.2.10 Bioluminescence imaging with Xenogen IVIS 200 (for luciferase expression in mice) ...................... 36 
2.2.11 Luciferase expression in vitro culture ................................................................................................ 36 
2.2.12 Computer programs and software analysis ....................................................................................... 37 
2.2.13 Histological sections .......................................................................................................................... 37 
2.2.14 Statistical evaluation .......................................................................................................................... 37 
3 RESULTS ...................................................................................................................................................... 38 
3.1. Crosstalk of transgene expression cassettes in randomly obtained sites in HEK293T cells and CHOK1 cells .. 38 
3.1.1 Tagging of genomic loci with FRT sites using lentiviral transduction .................................................. 38 
3.1.2 Expression analysis of CMV-GFP in HEK293T and CHOK1 clones ........................................................ 40 
3.1.3 Intraclonal variation in HEK293T and CHOK1 cell clones ..................................................................... 42 
3.1.4 Heterogeneity in expression is not correlated to CpG methylation in the CMV promoter ................. 47 
3.1.5 High GFP expression correlates to differential levels of active and repressive histone markings ...... 51 
3.1.6 Activation of transgene expression upon treatment with epigenetic modifiers ................................. 53 
  
 
3.1.7 Reanalysis of the GFP negative and positive sorted populations ........................................................ 55 
3.1.8 Expression profiles upon exchange of expression cassettes through recombinase mediated cassette 
exchange (RMCE) .......................................................................................................................................... 57 
3.1.8a Exchange of the reporter coding gene............................................................................................... 58 
3.1.8b Evaluation of a synthetic promoter construct in HEKCl17PS site ...................................................... 61 
3.1.8c Targeting a heterologous construct in the tagged loci in HEK293T and CHOK1 cell.......................... 64 
3.1.8d Evaluation of the methylation state of the SV40 promoter upon targeting in high expressing sites 66 
3.1.9 Summary of results on targeted integration ....................................................................................... 67 
3.2 Results Part 2 ..................................................................................................................................................... 69 
3.2 Crosstalk between synthetic construct in the Rosa26 locus................................................................... 69 
3.2.1 Expression analysis of RosaGFP mice .................................................................................................. 69 
3.2.2 Partial rescue of the transgene expression upon treatment with Dnmt inhibitors ............................. 72 
3.2.3 DNA methylation pattern of the BiTet promoter in the Rosa26 locus ................................................ 75 
3.2.4 Endogenous Rosa26 promoter and Thumpd3 promoter remained methylation free upon targeting 
the Tet driven constructs. ............................................................................................................................. 78 
3.2.5 Partial rescue of GFP expression upon treatment with Azacytidine and Decitabine in the RosaGFP 
mES cells ....................................................................................................................................................... 80 
3.2.6   Cell to cell heterogeneity in the Tet methylation pattern of RosaGFP ES cells ................................. 82 
3.2.7 Evaluation of a CpG free bidirectional Tet promoter in the Rosa26 locus .......................................... 84 
4 DISCUSSION ................................................................................................................................................ 87 
4.1 Spreading of DNA methylation .......................................................................................................................... 89 
4.2 Screening as a method to identify stable integration sites in cell lines and mice ............................................. 89 
4.3 Predictability of transgene expression upon targeted integration and its limitations ...................................... 91 
4.3.1 Targeted integration in preselected loci in HEK293T and CHOK1 ....................................................... 91 
4.3.2 Targeted integration in Rosa26 locus .................................................................................................. 92 
4.4 Epigenetic mechanisms involved in transgene silencing ................................................................................... 93 
4.4.1 Evaluation of transgene modulation in HEK293T and CHOK1 cell lines .............................................. 93 
4.4.2 Epigenetic influences on Tet promoter in Rosa26 locus ...................................................................... 94 
  
 
4.5 The CMV promoter and its sensitivity towards silencing .................................................................................. 95 
4.6 Potential factors responsible for transgene silencing ....................................................................................... 95 
4.7 The potential of epigenetic modifiers (Dnmt inhibitors and HDAC inhibitors) to alter chromatin state and 
recover transgene expression ..................................................................................................................................... 96 
4.8 Tetracycline inducible promoter in Rosa26 locus: The Rosa-Tet combination.................................................. 98 
4.9 Procollagen (Col1A1) locus as an alternative to Rosa26? .................................................................................. 99 
4.10 CpG free Tet promoter- A potential solution to overcome silencing ............................................................ 100 
4.11 Challenge to the concept of “Safe Harbors” .................................................................................................. 101 
5 Conclusion ................................................................................................................................................ 103 
6 Outlook ..................................................................................................................................................... 104 
7 Summary .................................................................................................................................................. 105 
8 REFERENCES .............................................................................................................................................. 106 
9 APPENDIX ................................................................................................................................................. 116 
9.1 LIST OF ABBREVATIONS ................................................................................................................................... 116 
9.2  LIST OF FIGURES .............................................................................................................................................. 120 
9.3 LIST OF TABLES ................................................................................................................................................. 121 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ABSTRACT/ ZUSAMMENFASSUNG 
 
 
 
ABSTRACT 
 
Heterogeneity in transgene expression is frequently observed upon genetic modification of 
cells in basic research and biotechnology. The variable transgene expression is considered to 
be a result of the crosstalk of the incoming promoter cassette with cis-acting elements 
associated with the chromosomal site of transgene integration (position effect). Targeted 
integration of the transgene into the open chromatin reduces variability due to 
chromosomal position effects and also favors the more predictable transgene expression. 
The objective of this study was to have a mechanistic understanding of the nature of 
interaction that occurs between the transgenic/synthetic cassettes when integrated into 
defined chromosomal sites. To this end CMV driven transgene expression were investigated 
in more than 100 independent cell clones in two different cell lines (CHO and HEK293T). Not 
only was the transgene expression highly variable among clones but also large levels of 
heterogeneity in expression existed within clones with metastable phenotype. This was 
correlated with differential and dynamic chromatin conformation related to differential 
histone modifications. In addition, a CMV based Tetracycline inducible synthetic promoter 
(BiTet) was evaluated in the well-characterized Rosa26 locus.The epigenetic status of the 
promoter cassette was evaluated in mouse ES cells and transgenic mice to investigate the 
mechanisms mediating the interaction between the transgene and the chromosomal loci 
that results in variation of transgene expression. Contrary to the expectation, even upon 
targeting the ubiquitous Rosa26 locus, the expression of the synthetic cassette driven by 
tetracycline inducible synthetic promoters (BiTet) was highly heterogeneous. However in 
this analysis the endogenous Rosa26 locus largely remained methylation free. While DNA 
methylation was the major player in the silencing of the Tetracycline based promoter 
systems in the Rosa26 site, the heterogeneity associated with the hCMV driven constructs in 
random CHO and HEK293T clones was entirely associated with distinct histone modifications 
causing variable transgene expression and transgene silencing. While the heterogeneous 
expression was found to be associated with different chromatin states conferred by various 
epigenetic markings, the stability and extent of the variation in transgene expression may 
largely depend on the nature of crosstalk between the chromosomal integration site and 
the synthetic construct.  
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ZUSAMMENFASSUNG 
 
Genetisch manipulierte Zellen werden oft in der Biotechnologie und der 
Grundlagenforschung verwendet. In diesen  genetisch manipulierten Zellen kommt es oft zu 
unerwünschten heterogenen Transgen-Expressionen, die oft ein Nebeneffekt von 
sogenannten Positionseffekten sind.  Diese Positionseffekte entstehen durch die Interaktion 
der Promoter-Kassetten mit den im Genom codierten Cis agierenden Elementen, was zu  
unterschiedlichen  Transgenexpressionen führt. Die gezielte Integration eines Transgens in 
einen offenen Chromatin-Abschnitt reduziert den sogenannten Positionseffekt und führt zu 
einer vorhersagbareren Expression.Das Ziel dieser Arbeit ist die Untersuchung von 
transgenen/synthetischen Kassetten an verschiedenen  chromosomalen Integrations-Orten 
um die sogenannten Positionseffekte und den chromosomalen „crosstalk“ genauer zu 
charakterisieren. Von zwei verschiedenen Zelllinien (CHO und Hek293T) wurden 100 Klone 
analysiert. Diese Klone wurden auf die Expression der integrierten Transgen-Kassette 
überprüft. Hierbei wurde das Transgen von einem CMV Promoter exprimiert. 
Zum Einen zeigte die Analyse der Zellen, dass die einzelnen Klone mit der gleichen 
Transgenkassette an verschiedenen Integrationsorten unterschiedliche Expressionsmuster 
aufwiesen (interklonale Expressionsunterschiede). Interressanterweise änderten sich zum 
Anderen diese Expressionsmuster der analysierten Klone nach mehrmaligen passagieren 
(Intraklonale Expressionsunterschiede). Das heisst, dass Zellen mit der gleichen 
Transgenkassette an dem gleichen Integrationsort  ihr Expressionsmuster verändern. 
Diese intraklonalen Unterschiede wurden als metastabil bezeichnet.  Die unterschiedlich 
exprimierenden Zellen in den metastabilen Klonen wurden genauer charakterisiert. Hierbei 
korrelierten die verschiedenen Expressionsmuster mit den unterschiedlichen Histon 
Modifikationen und somit  mit den chromatin Konformationen. Zusätzlich wurde ein CMV 
basierter synthetischer Promoter, Tetracycline abhängiger Promoter (BiTet), in einem gut 
charakterisierten Lokus, dem R26 Lokus, analysiert. Obwohl der Promoter (BiTet) in diesem 
ubiquitär aktiven Lokus integriert wurde, zeigte die Expressionsanalyse,  sowohl in Maus-
Stammzellen als auch in transgenen Mäusen, überraschenderweise eine heterogene 
Expression. Anhand der epigenetischen Analysen konnte gezeigt werden, dass der Bitet 
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Promoter methyliert wird, wobei der endogene R26 Promoter hauptsächlich frei von 
Methylierungen bleibt.Während das Silencing der Bitet Kassette in dem R26 Lokus und 
somit die heterogene Transgenexpression hauptsächlich auf die Methylierung der DNA 
zurückzuführen ist, ist das Silencing der analysierten CHO und HEK293T Klone, die zufällig im 
Genom integrierten,  ein Resultat der Histon Modifikationen.Nichts desto trotz, während die 
Heterogenität der Transgenexpression von verschiedenen Chromatin-Zuständen, die über 
bestimmte epigenetische Markierungnen etabliert werden, abhängt, ist die Stabilität und 
die Stärke der heterogenen Expression abhängig von der Interaktion des synthetischen 
integrierten Konstrukts und des chromosomalen Integrations-Ortes. 
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1Introduction 
 
1.1 Epigenetic role play in gene expression 
 
It was long held that the enormous wealth of information stored in the genome sequence of 
an individual’s to a large extent determines the phenotypic outcomes. The human genome 
project was thought to solve many riddles, however, that data suggest that only about 
30,000 genes are involved in the functional existence of the most complex organisms on the 
planet. In spite of the abundance of the information it is still quite vaguely known how this 
information is managed, released and maintained. Studies have shown that inspite of the 
same complement of genetic material incase of twins, the phenotypic variations have been 
large. Such discordance between the genotype and phenotype has been associated with the 
epigenetic modulations of the underlying genotype.  
These modulations are considered to be responsiblefor the alteration in the function of 
genes without a change in the genome sequence. The field of research dealing with such 
kind of mechanisms is known as “epigenetics”, and involves chemical modifications like 
methylationoccurring on the cytosine residues of the DNA and also modifications of histone 
residues such as acetylation, phosphorylation and methylation (Figure 1). The term "epi" 
means "above/over”, suggesting the location of the modifications with respect to the DNA 
sequence. The epigenetic modification forms a kind of shell covering as well as interacting 
with the core information in the genetic sequence in the body. This interaction results in 
additional information that governs the differential expression of genes.These epigenetic 
mechanismsplay an important role during the development stages in an organism where 
about 200 different cell types sharing an identical genotypearise from a single cell. Its 
importance in the differentiation process is also evident from the fact that different 
progenitor cells, again sharing same genotype, form a variety of cell types with diverse, yet 
stable, profiles of gene expression and distinct cellular functions. 
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Figure 1:  Epigenetic regulatory mechanisms. A) The organization of DNA with histone. B) 
Modifications of histones H3 tail residues such as lysine (K) and arginine(R). C) In addition,cytosines of 
the CpG motif undergo methylation on the DNA level (figure adapted from Penner et al(1)). D) 
Epigenetic modifications such as acetylated histones and demethylated cytosine favor open 
conformation thereby favoring transcription. Deacetylated histones and methylated cytosine favor 
closed conformation thus repressing transcription of genes. 
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The differential epigenetic markings on DNA and histones alter the conformation state of 
chromatinEpigenetic marks like acetylation of histones, trimethylation of histone H3 lysine 
4, unmethylated cytosine etc make chromatin more accessible for transcription factors to 
bind and thereby supporting the gene expression.On the other hand epigenetic marks such 
as methylation of DNA,deacetylation of histones, trimethylation of histone H3 lysine 9 and 
histone 3 lysine27 are some of the epigenetic marks present at the condensed chromatin. 
The condensation of chromatin thus preventing the binding of transcription factors leading 
to silencing of gene expression(2-6). 
The following chapters will focus on DNA methylation and some modifications of histones in 
more detail since they represent well characterized mechanisms and form an integral part 
of epigenetic regulation. 
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1.2 DNA methylation 
 
One of the most well characterized and known epigenetic modification is that of DNA methylation 
that involves covalent addition of a methyl group to the 5' carbon atom of cytosine (C)(7). In 
mammals, this modification mainly occurs to cytosines that are succeeded by guanine (G), thus 
forming the CpG dinucleotides (CpGs).These CpG dinucleotides are not uniformly distributed. 
Rather, they occur in clusters, thereby forming a kind of islands on the otherwise CpG devoid 
genome (so-called CpG islands, CGIs) (8-11). One plausible explanation for non-uniform distribution 
of CpGs might be that methylated cytosines(5mC) undergo hydrolytic deamination yielding thymine 
(T). Thymine is a naturally occurring genomic base and is not recognized by the repair system of the 
cells. Thus, deamination of 5mC results in a C to T transition. This might have accounted for the 
asymmetric distribution of the CpGs during the course of evolution. 
The classification of a region into a CpG island is based  on the following criteria: 1) an 
overall GC content of 50 % or higher 2) The observed versus expected ratio of CpG 
frequency of 0.6 in a region of 200 base pairs minimum(10).  Interestingly, CpG 
dinucleotides are distributed unequally over the genome.In most cases methylation of the 
CpGs is associated with gene silencing and is considered to play an essential role in 
embryonic development (11), cell differentiation and dedifferentiation (12), genomic 
imprinting(13,14), X-inactivation in mammals(15)and silencing of potentially harmful DNA 
elements like transposons or endogenous retroviruses(16). 
 
The addition of the methyl group from the methyl group donor (mostly S-adenosyl 
methionine, also abbreviated as SAM) to the 5’carbon of cytosine is catalyzed by enzymes 
called DNA methyltransferases (Dnmt) (Figure2B).In eukaryotes, three different families of 
DNA methyltransferases have been identified, namely Dnmt1, Dnmt2 and Dnmt3 with the 
two subclasses 3a and 3b(17). Although the mechanism of action is similar, they differ in 
their biological roles. Dnmt1 is responsible for maintaining the methylation pattern during 
the replication in the S phase of the cell cycle. It copies the methylation marks onto the 
daughter strand from the hemimethylated parent strand (Figure 2C). It exhibits a 5-10 fold 
higher affinity for hemi-methylated DNA (18,19). The functional role of Dnmt2 has not been 
clearly elucidated, however, it is proposed that Dnmt2 might be playing a role in RNA 
methylation (20,21).Dnmt3a and Dnmt3b are responsible for de novo DNA 
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methylation(Figure 2C). They become active during early stages of developmentand are 
essential in the establishment of new methylation patterns and following correct 
development (22,23). Dnmt3L does not have a catalytic function of its own but studies have 
shown that it also plays a role in catalytic activity of de novo methyltransferases(24) 
 
With the growing importance of DNA methylation mediated gene silencing and its role in 
cancer and other diseases (17,25), the search for the inhibitors of DNA methyltransferases 
lead to the discovery of chemicals like Azacytidine and Decitabine. These were then 
followed by the identification of various different chemical drugs. However, these two 
remained the most widely used Dnmt inhibitors. . They  represent nucleoside analogues and 
upon phosphorylation in the cells, they are incorporated into the DNA or RNA(Figure 
2D)(26). While the incorporation of Azacytidine has been shown to be preferential for RNA, 
Decitabine prefers the DNA(27). Mechanistically, Azacytidine (Aza) and Decitabine (Deci) get 
incorporated into the DNA after being metabolized to 5-aza-2′-deoxycytidine-triphosphate 
which substitutes for cytosine. Azacytosine-guanine dinucleotides are recognized by the 
DNA methyltransferases as a natural substrate. Dnmt enzymes will initiate the methylation 
reaction by a nucleophilic attack. This results in the establishment of a covalent bond 
between the carbon-6 atom of the cytosine ring and the enzyme. The bond is normally 
resolved by beta-elimination through the carbon-5 atom, but the reaction is blocked with 
azacytosine, where carbon-5 is substituted by nitrogen. Thus, the enzyme remains 
covalently bound to DNA and its DNA methyltransferase function is blocked. In addition, the 
covalent protein adduction also compromises the functionality of DNA and triggers DNA 
damage signaling, resulting in the degradation of trapped DNA methyltransferases. As a 
consequence, methylation marks become lost during DNA replication. With repeated 
divisions DNMTs are blocked by being bound to these drugs. As a consequence of this, 
significant demethylation can be observed. 
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Figure 2: DNA methylation reaction catalyzed by Dnmts. A) Presence of DNA methylation on the 
chromatin. B&C)the DNA methylation reaction catalysed by DNA methyltransferase 
(denovo(dnDNMT)) and maintaince(mDNMTs) in presence of S-adenosyl methionine (SAM) (Figure 
adapted from Day et al(28)). D) Structures of Azacytidine and Decitabine (Dnmt inhibitors)  
 
1.2.1 Role of DNA methylation in healthy cells, in transcriptional regulation and in 
cancerous cells 
 
DNA methylation is an ancient process found in all domains of life. In eukaryotes, which 
include diverse organisms such as plants as well as humans, DNA methylation is found 
exclusively at cytosine residues (29-31). Several studies have indicated the essential role of 
d
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DNA methylation in proper development of a multicellular organism(32). DNA methylation 
has been proposed to be an important role player in mammalian development in 
establishing the correct pattern of gene expression. Whether it is X chromosome silencing or 
transposon silencing, the role of DNA methylation has been shown to be imperative(16,18). 
The observation that mice lacking Dnmts die very earlyduring embryogenesis suggests that 
this modification has important roles and is essential for mammalian embryonic 
development(33).Embryos show reduced DNA methylation levels but the specific reasons 
for death during development remain unclear. Defects in repression of the inactivated X 
chromosome in female cells and in the establishment and maintenance of allele-specific 
expression of imprinted genes have been observed(34). Thus, lethality might result from 
aberrant gene dosage.  
 
The role of DNA methylation in a normal cell can also be evaluated on the basis of the exact 
location of the methylation. The promoter methylation of oncogenes has been associated 
with the inactivation of oncogenes whereas aberrant methylation can lead to uncontrolled 
proliferation resulting in cancerous growth(35). Also the promoter methylation plays a role 
to suppress the activity of lineage specific genes allowing for specific expression of genes in 
a lineage specific manner. 
 
High levels of DNA methylation are also associated with Alu repeats elements that are kept 
in a silenced state. In Dnmt-knockout mice, global demethylation as a consequence of 
Dnmt1 absence likely triggers mutations through the activation of cryptic transposons, 
which might contribute to early lethality (36,37). Normally these transposons are 
methylated and thereby repressed. Consequently, DNA methylation masks the effects of 
transposon insertion by mechanisms that do not directly depend on regulation of 
transcription or transposition.  
 
However, the evolution of DNA methylation has been found to be more ancient in case of 
the gene bodies and intragenic regions. Also in most of the invertebrates, DNA methylation 
predominantly occurs in the gene body regions (7,16,30,31). These studies have also 
suggested that the gene body methylation might have evolved before the promoter 
methylation. The gene body methylation has been hypothesized to reduce transcriptional 
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noise (38,39). These transcriptional noises might be due to the phenomenon of transcription 
occurring in patches rather than continuously, a process called transcriptional bursts 
(16,40,41). Another reason for the noise can be transcription from non-canonical 
promoters, potentially due to overabundance of RNA polymerase II in the cellular 
environment(16) which are thereby repressed by DNA methylation.  
The study by Huh et al found a negative correlation between the gene body methylation and 
transcriptional noise supporting the hypothesis that the gene body methylation evolved to 
suppress the transcriptional noise (16,31) thereby reducing the production of transcripts 
from non-canonical promoters and reducing the waste consumption of energy. The same 
group showed that differential gene body methylation in prefrontal cortex and blood 
resulted in significantly different transcriptional noise with less transcriptional noise in brain 
(more methylated) than blood(less methylated) (16). 
Cancerous cells have been characterized by aberrant methylation profiles with general 
hypomethylation in the intergenic regions and at oncogenes. However, they provide a 
hypermethylated state at the tumour suppressor genes, thus silencing them and creating a 
perfect environment for unchecked growth due to expression of Hypomethylated 
oncogenes.  
1.3 Histone mediated gene modulation 
 
Histones form the main protein component of the chromatin with DNA wrapped around 
them. The basic unit of chromatin, the nucleosome, is formed by a histone protein octamer. 
This octamer is formed of two molecules of each of four core histones H2A, H2B, H3 and H4 
with 147bp of DNA wrapped around(42-44). Various modifications of histones have been 
found on different amino acid residues. These include phosphorylation of threonine, serine 
and tyrosine(45). Also arginine can undergo mono, di, or tri methylation. However, most 
commonly studied modifications include the acetylation and methylation of lysine residues. 
All these modifications can have a different role in gene expression depending on the kind 
of modification and on the particular residue being modified. In general, acetylation of 
histones have been associated with the active gene transcription where as methylation can 
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have both activating (H3K4me3) as well as repressive (H3K9me3 and H3K27me3) effect on 
the chromatin(45). 
1.3.1 Crosstalk between histone modifications and transcriptional regulation 
 
The presumption that a specific histone modification has a specific effect on transcriptional 
regulation (activation or repression)might hold true for modifications like acetylation which 
is activating and SUMOylation which is generally repressing (46). However, in most other 
cases the scenario is more complex with evidences of a complex crosstalk existing between 
different histone modifications. For example in spite of being mutually exclusive and having 
completely opposite roles, both H3K4 methylation and H3K9 methylation were shown to 
have a crosstalk where the increase in levels of H3K9 methylation leads to decrease in H3K4 
methylation and vise-versa(47). Another interesting case is that of H4K20 methylation 
where the extent of methylation determines the overall acetylation levels on H4. In this case 
the monomethylation of H4K20 leads to hyperacetylation and hence gene activation 
whereas the trimethylation of the H4K20 leads to gene repression (44,48,49). 
Thus the histone mediated gene regulation presents an example of complex network of 
regulatory modifications that may function in a highly ordered manner depending upon the 
crosstalk that occurs between them. Most common histone markings and their effect on 
gene expression is summarized in Table 1. 
 
 
 
 
Type of histone modification Abbreviation Function 
Histone3lysine4trimethylation H3K4me3 Gene activation 
Histone3lysine4 acetylation H3K4ac Gene activation 
Histone3lysine9trimethylation H3K9me3 Gene repression 
Histone3lysine27trimethylation H3K27me3 Gene repression 
Histone3lysine27acetylation H3K27ac Gene activation 
Histone3lysine20trimethylation H3K20me3 Gene activation 
Histone3lysine36trimethylation H3K36me3 Gene activation 
Histone3lysine79 dimethylation H3K79me2 Gene activation 
Histone3lysine79trimethylation H3K37me3 Gene activation 
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Table1: Summary of the most common histone markings and their respective association 
with the gene expression. 
 
1.3.2 Histone code hypothesis 
 
The histone code hypothesis was suggested in 2000 by Stahl and Allis, according to 
whichvarious combinations of histone modifications can act in concert to determine the 
activity at a particular genomic locus (50-52). According to this, combinations of specific 
histone markings can act when they are present on same histone tail or on different histone 
tails within the same nucleosome to bring about a specific output. 
The hypothesis was bolstered by different studies showing that this kind of crosstalk 
occurred between different modifications such as ubiquitylation of H2B and methylation of 
histone H3 lysine 79 ,where pre ubiquitylationwas necessary for methylation of H3K79 
(53,54). Another study showed that phosphorylation of serine 10 lead to decrease in 
trimethylation on lysine9 of histone H3. The reason for this was that the phosphorylation of 
serine 10 interfered with methylation reaction itself at lysine 9 on histone H3 which was 
catalysed by lysine methyltransferase called SUV39H1. (50). Thus, depending upon the kind 
of crosstalk, different outcomes are possible. However the exact analysis of different kinds 
of modifications comprising Histone code remains to be fully investigated. 
 
1.3.3 Crosstalk between DNA methylation and histone modification 
 
Generally, it is observed that both, the modification on the DNA and histones, act together 
and can influence each other. Studies from McCabe et al, 2009 showed that histone 
modifications play an important role in targeting the Dnmts for methylation of the DNA(55). 
In another study, Lehertz et al 2003 showed that there exists an important link between 
H3K9 methylation and DNA methylation with the H3K9 methylation being an important step 
in recruitment of Dnmt in the pericentromeric repeat regions (56). Also it was shown that 
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for maintaining the DNA methylation,certain histone modification played an important role 
(57). 
1.3.4 Histone deacetylases and their inhibitors 
 
Acetylation of the lysine ε-amino group is brought about by lysine acetyltransferases (KATs) 
whereas the opposing activity is shown by histone deacetylases (HDACs). The acetylation of 
histones is known to lead to an open chromatin structure and to active gene transcription. 
On the contrary, deacetylation is usually related with gene silencing. HDACs fall into 4 
different classes according to their homology to their yeast counterpart(58-60). Although 
the most commonly studied are from class I and II. Class III has recently gained importance 
with implied roles in aging .A summary of various classes and their members are 
summarized in Table 2. 
 
HDAC class Location Members Cofactors 
Class I Present in nucleus 
HDAC1,HDAC2,HDAC3 
and HDAC8 
Zn++ dependent 
activity 
Class II 
Shuttle between 
nucleus and 
cytoplasm, 
HDAC4,HDAC5,HDAC6, 
HDAC7, HDAC9 and 
HDAC10 
Zn++ dependent 
activity 
Class III Nucleus 
They contain seven 
sirtuins 
NAD+ cofactor 
dependent activity 
Class IV Nucleus/cytoplasm 
HDAC11 
Zn++ dependent 
activity 
 
Table2: Summary of various different classes of HDACs and the their cofactors involved in 
the deacetylation reaction 
Most of the HDACs and KATs do not bind directly to a particular DNA motif but interact 
through multiprotein complexes involving corepressors and coactivators(61). HDAC1 and 
HDAC2 for example form homo- and heterodimers in multiprotein complexes such as those 
 INTRODUCTION 
12 
 
involving Sin 3A or B or CoREST which are involved in transcriptional repression or with 
chromatin remodelers such as NuRD(58,59). 
1.3.5 Action of Valproic acid (VPA) and sodium butyrate 
 
To modulate the histone acetylation HDAC inhibitors (HDACi) have been identified. Most of 
the HDACi used today have Zn++ chelating groups owing to which they can fit into the active 
pockets of HDAC from class I, II and IV and disrupt the formation of multimeric protein 
complexes(62). 
The HDAC inhibitors VPA and sodium butyrate are mild inhibitors of HDAC class1 enzymes 
(63,64). These were shown to have highest affinity for the CoREST complexes followed by 
NuRD and least for Sin3 mediated HDAC inhibitions(65,66). 
 
1.4 Transgene silencing and Position effect 
 
There are different ways a gene can be silenced. This can be attained at the level of 
transcription called transcriptional gene silencing (TGS) and at the level of post 
transcription, called posttranscriptional gene silencing (PTGS). As the thesis focuses 
primarily on the transcriptional gene silencing, it will be discussed in more detail. 
Transcriptional gene silencing is achieved by the changes in the chromatin states mediated 
by the alteration in the levels of DNA methylation and the dynamics of histone modification. 
Most of our understanding of the epigenetic role play in differential gene expression is 
based on cellular genes in their natural environment. In contrast, much less is known about 
the crosstalk of heterologous/synthetic/transgenic regulatory elements once integrated into 
a specific chromosomal domain as it occurs upon genetic modification of cells. Indeed, once 
transgenes are integrated into the chromosomal DNA, a high clone to clone variation of 
transgene expression is observed. This is generally described as the chromosomal position 
effect(67-71).  The ‘position effect’ comprises the influence of genetic elements such as 
enhancers which facilitate binding of transcription factors and thereby modulate the 
incoming promoter. In addition, it is conveyed by epigenetic modification of the incoming 
cassette. Indeed, these epigenetic effects have been shown to contribute to gene silencing 
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in vivo(72)and in vitro(2,73). This variation of expression is a concern for biotechnology 
whereuniform and stable transgene expression is required (74) but also when generating 
transgenic animals(75).  
The focus of the current thesis is mainly on the epigenetic modulation affecting the 
transgene in a chromosomal locus.  In the centre of this thesis is the Cytomegalovirus (CMV) 
promoter as a frequently used, highly potent promoter for driving the transgene. In 
addition, the thesis concerns induced expression by employing a Tetracycline inducible 
promoter based on the CMV promoter. 
1.5 The CMV and the Tetracycline inducible promoter elements 
 
1.5.1CMV promoter 
 
The human immediate-early CMV (Cytomegalovirus) promoter is one of the most commonly 
used promoter elements for transient and stable transgene expression in plasmids as well as 
in viral vectors (76-78). The CMV promoter has been shown to confer ubiquitous expression 
and to display less tissue specificity(79). 
 
1.5.2 Synthetic Inducible promoter (Tetracycline inducible promoter) 
 
Based on a minimal CMV promoter that has only the TATA box for initiation of transcription, 
the Tetracycline induced promoter was developed. The Tet promoter is the most commonly 
and widely used inducible promoter system.The Tet system is composed of two elements: 
the Tet promoter and its transactivator proteins.The originally described tet promoter is 
composed of the minimal hCMV immediate early promoter (80) and a seven tet operator 
repeat sequences from the E. coli tetracycline operon (80). These so-called tetracycline 
responsive elements (TRE) are the binding sites for the transactivator protein (tTA or rtTA) 
which leads to strong transcription activation. The Tet on system is based on the ability of 
the rtTA transactivator protein to bind to the operator elements only in presence of the Dox 
(81). 
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Both unidirectional and bidirectional Tet promoters have been developed. The 
unidirectional Tet promoter has one minimal hCMV region fused to the operator regions 
(80,81). In addition, a bidirectional Tet promoter has been developed which had two 
minimal hCMV regions flanking the 7 operator repeats regions(82). The bidirectional 
promoter has several advantages such as: 1) it allows for co-expression of two gene 
products in stoichiometric amounts, 2) a reporter can be combined with non-easily 
assayable gene of interest and can be monitored with the help of reporter(83). 
 
 
 
 
Figure 3: The Tet on system. A) The Tet-on system comprises of two components i.e thertTA 
transactivator and the synthetic promoter. In this system, the administration of Doxycycline renders 
the transactivator proteins binding. Thereby, Tet based transcription is activated. Transcription is 
stopped by removing the Doxycycline from the medium. 
 
 
Operator CMVmin
Transactivator
proteins
on +dox
-doxoff
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1.5.3 Utility of inducible promoter system (Tet system) 
 
The temporal control of gene expression can be useful in cases where the experimental 
studies involve the expression of toxic and xenobiotic compounds or the study of genes that 
are embryonic lethal thus are difficult to study (84,85). The Tet system has also been used to 
look for the disease progression with expression of certain mutant or viral proteins (86,87), 
and thus it provides the researcher with a great tool to investigate questions that can be 
difficult to answer in normal experimental settings 
 
 
 
1.5.4 Optimization of Tet promoter 
 
Since its synthesis by Gossen and Bujard(80) several studies have been aimed at optimizing 
it further. Most of these are based on the manipulation of the transactivator proteins. These 
included codon optimization (88-90), introduction of nuclear localization signal (NLS)(91,92) 
and removal of potential splice sites(89). Another important factor was the basal expression 
from the Tet promoter.The basal expression of the Tet promoter might arise from various 
different transcription factor binding sites that are present in the Tet promoter (93). These 
include ISRE motifs located between operator (tetO), the GATA factors (WGATAR, whereWis 
A or T andR is A or G) that exactly overlie the consensussequence for the tetR 
(TCCCTATCAGTGATAGAGA)(93). Additionally,the murine (m) CMV element ofthe Ptethas 
AP2(94), cAMP-response element 1, xenobioticresponseelement 1, GCF, IFN-g, and LFA-1.In 
an effort to  reduce the basal expression in non induced state, the consensus sequences in 
the TATA box and TFII binding sites were mutated and also the 5’UTR region was 
truncated(83).  
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1.6 Transgene integration sites within the chromosome 
 
The chromosomal integration sites for transgene expression have been a topic of immense 
interest. The possibility of the presence of a site that supports high transgene expression 
“the so called genomic hotspot”and its great economic value has lead to a great expectation 
and extensive search for such a site. These hotspots can be used for high, stable and 
predictable transgene expression (95).  
In the murine genome few genomic locations have been reported to support ubiquitous and 
stable expression of the synthetic cassette (96,97). Among these, the Rosa26 has been the 
most commonly used for mouse transgenesis(97) 
 
1.6.1 A well known integration site: the Rosa26 locus 
 
The well-known Rosa26 locus on chromosome 6 was first found in a gene trap experiment in 
mouse ES cells(97). It has been targeted since and has been used in a number of labs around 
the world to generate transgenic mice upon integration of transgenes by homologous 
recombination (98-100).The major advantage of the Rosa locus is its ubiquitous expression 
through different developmental stages. 
 
Figure 4: The Rosa26 locus (not to scale). The Rosa26 locus is present on chromosome number 6 in 
the mouse genome. The Rosa26 promoter is a bidirectional promoter harbouring a CpG island of 
roughly of about 1.5kb. Two transcripts are generated, the Rosa transcript and the Setd5 transcript. 
The Thumpd3 gene is present with another classical CpG island promoter about with a distance of  
10kb from the Rosa promoter. 
Thumpd3 SetD5Rosa 26
10kb 54kb
CpG island 
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The utility of this locus over last decade has triggered the search for the corresponding 
Rosa26 locus in other genomes such as in rats(101), humans(102). The technological 
advancement has also lead to generation of targeting tools such as zinc fingers that can be 
used to directly target the Rosa26 locus (103,104) 
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1.7 Targeted integration through recombinase mediated cassette exchange 
(RMCE) 
 
To deal with the heterogeneity of gene expression upon random integration of cassettes 
into the host’s chromosomes, standard protocols employ screening procedures to identify 
those integration events that meet the requirements for transgene expression (e.g. stable or 
regulated expression). This imposes a limitation, in particular when resources for screening 
are restricted and/or if the monitoring of transgene expression is not straightforward. Thus, 
efforts have been undertaken to develop novel strategies for predictable, reliable, and, 
most importantly, effective manipulation of mammalian cells. The recently emerged 
methods are designed to target expression cassettes to preselected chromosomal loci, in 
particular chromosomal sites which support high level of expression (so called ‘hot spots’). 
Following such strategies, the unpredictability associated with the random integration of 
expression cassettes is overcome or at least reduced since the modulation mediated by the 
particular chromosomal site is known. In particular, when repeatedly the same integration 
site is used the requirement for large scale screens for every new transgene that needs to 
be expressed is obviated.  
Site specific recombinases were exploited for highly efficient modification of chromosomal 
loci in mammalian cells. The two major family members of tyrosine recombinases are Cre 
and Flp. Cre(causes recombination) recombinase was derived from the P1 bacteriophage. 
The 34bp recombination target (RT) site for Cre was named loxP (locus of crossing (x) over, 
P1). The other tyrosine recombinase, Flp, was identified in Saccharomyces Cerevisiae. Flp 
recombinase recognizes and binds to their sites, called the FRT sites, comprising three 
repeat regions flanking the unique spacer sequence(105).In a first step, a single RT or a set 
of specific RT(s) are integrated into the genome of a cell line (so-called tagging). This can be 
achieved by transfection or infection of an expression vector that carries the RT(s). Upon 
random integration of this vector and screening, cell clones are isolated that provide the 
appropriate expression pattern (e.g. high, stable or regulated transgene expression). 
Alternatively, the RT site(s) can be specifically integrated into defined chromosomal loci by 
homologous recombination. In a second step, such cell clones are then targeted with a gene 
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of interest by simple co-transfection of a vector harboring the RT(s) and a vector encoding 
the recombinase. As a result of the site specific recombination, integration of the cassette is 
achieved (‘targeting’)(106-108).  
1.7.1 Recombinase mediated cassette exchange (RMCE) 
 
In recombinase mediated cassette exchange (RMCE) targeting is a “cut and paste” 
mechanism that involves recombinase mediated excision of a DNA segment flanked by a set 
of two heterologous RTs and integration of a cassette flanked with the very same set of RTs. 
Thereby, an exchange of the intervening sequences is achieved. A prerequisite for RMCE is a 
set of heterologous RTs that cannot recombine with each other (Fig. 5)(105). 
 
 
 
 
 
 
 
 
 
Figure 5: RMCE: Two heterospecific, non-interacting RT sites in the genome will recombine with 
identical RT sites delivered by an external plasmid resulting in recombinase mediated cassette 
exchange in presence of Flp recombinase. The reverse reaction is kinetically and thermodynamically 
unfavoured and virtually excluded (Figure from Kruse et al.(105)) 
RMCE
FRT
FRT
FRT*
FRT*
FRT*FRT
Flp
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With simple easy to use protocol, the use of recombinase based genome modification has a 
popular method of choice over the last years It has been used in various different fields in 
basic science and also biotechnology including the generation of recombinant protein 
expressing cell lines and also in the generation of a wide variety of transgenic mice 
(e.g.(99)). Basically, the concept allows to screen integration sites using reporters that 
facilitate easy detection (e.g. GFP) and to establish these clones as master cell lines for 
targeting cassettes of choice. Due to the fact that targeting is fast, efficient and precise and 
the genetic manipulation is defined, the expression properties of the final producer clones 
are predictable(105,108).  
Meanwhile, there are a number of examples that exemplifies the efficient generation of cell 
lines using  thetargeted integration of expression cassettes that express a gene or vector of 
interest. However, some studies also pointed out that the exploitation of the potential of 
defined integration sites critically depends on the careful design of the incoming targeting 
vectors(105).The following example might illustrate this. 
A study by Gama-Norton et al. looked into  the impact of the orientation of the targeting 
cassette in two distinct loci in 293 cells that were identified because of their capability to 
support high expression of retroviral vectors. They observed that upon targeting three 
different cassettes in sense and antisense orientation using RMCE, one of the loci could 
support expression of either orientation and in the other locus the high expression levels 
were only achieved when the targeting cassettes were integrated in the same orientation as 
the initial tagging vector while expression dropped up to 100 fold for the other orientation 
(105,109).  
The RMCE based strategy can also be applied to express proteins other proteins.The work 
from Schucht and coworkers (110)to express G protein coupled receptors (GPCRs) from a 
master cell lines developed using this technology. Also, Wilke et al. used RMCE in mutant 
CHO Lec3.2.8.1 cells to produce glycoproteins with the well-established glycosylation 
pattern in a homogenous form (111). 
Highlighting the major application of the RMCE technology was the study from Wiberg et al 
who produced human polyclonal anti-RhD antibody in CHO cells (105,112). Individual 
antibody expression cassettes were targeted into the same chromosomal site and these cell 
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clones expressing individual antibodies were mixed to generate cell pools. These pools gave 
rise to the production of a polyclonal antibody in a highly reproducible manner allowing a 
direct industrial application.Similar observations were obtained for various promoters 
integrated into the Rosa26 locus of mouse embryonic stem (ES) cells (105,113). 
Together, these studies indicate that high expression potential of a chromosomal site can be 
exploited fairly nicely by means of targeted integration; however this high expression 
potential of chromosomal loci is also partlydependent on the cassette design. The sites 
favouring high, stable, and homogenous expression of transgene is highly desirable for 
expression of not only biotechnologically relevant proteins but also in basic research that 
rely on using transgenic models for investigation important bio-medically relevant 
questions. However, the underlying mechanism of crosstalk that occurs between an 
integration site and the incoming transgene has not been investigated. And although the 
RMCE based method allows for the repeated use of an integration site however how 
different transgenes are impacted epigenetically in a particular integration site remains 
unclear.  
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1.8 Aim of the study 
 
Heterogeneity in transgene expression is frequently observed upon genetic modification of 
cells in basic research and biotechnology. The variable transgene expression is considered to 
be a result of the crosstalk of the incoming promoter cassette with cis-acting elements 
associated with the chromosomal site of transgene integration (position effect). Targeted 
integration of the transgene into the open chromatin limits this variability caused due to the 
chromosomal position effects thereby rendering higher predictability in transgene 
expression. However, this does not shield the integrated transgene from the epigenetic 
influences.  
The objective of this study was to have a mechanistic understanding of the nature of 
interaction that occurs between the transgene cassettes when integrated into defined 
chromosomal sites. In particular, the underlying epigenetic mechanism like DNA 
methylation and histone modifications was to be elucidated. This concerned on the one 
hand the modulation of expression upon integration of CMV promoter driven transgenes 
into a specific site of integration in the HE293T and CHOK1 cells. Also, the epigenetic 
crosstalk was evaluated upon integration of synthetic Tet driven construct in the well known 
Rosa26 locus in transgenic mice. 
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2 MATERIAL AND METHODS 
2.1 Materials 
2.1.1 Equipment 
Instruments Manufacturer 
MassARRAY Compact System  Sequenom, Hamburg, Germany  
MassARRAY MATRIX Liquid Handler  Sequenom, Hamburg, Germany  
MassARRAYPhusio chip module  Sequenom, Hamburg, Germany  
Megafuge 3,0 R  Heraeus, Osterode, Germany  
Microarray hybridisation chambers 
SureHyb 
Agilent Technologies, Böblingen, Germany  
Microarray scanner; 5 micron resolution  Agilent Technologies, Böblingen, Germany  
Microarray slide holder  Agilent Technologies, Böblingen, Germany  
Microscopes  Zeiss, Jena, Germany  
Multifuge 3S-R  Heraeus, Osterode, Germany  
MultipipettorMultipette plus  Eppendorf, Hamburg, Germany  
NanoDrop PeqLab, Erlangen, Germany  
PCR-Thermocycler PTC-200  MJ-Research/Biometra, Oldendorf, Germany  
PCR-ThermocyclerVeriti 384 well  Applied Biosystems, Foster City, USA  
  
-20° C freezer Liebherr 
- 80°C freezer Thermo Forma 
4 °C refrigerator Liebherr 
BLI system Xenogen IVIS system, Caliper 
Cell Counter Guava EasyCount, Millipore  
CO2 Incubators for Cell Cultures Labotect 
Cooling Centrifuges HettichRontana/S 
 SorvallSuperspeed 
 MinifugeHeraeus-Christ 
 HeraeusBiofuge fresco 
 Inflexible rotors 
 Swing rotor 
Dionized Water Supply Millipore MilliQ 
Flow Cytometer FACS Calibur, BD Biosciences 
Gel Electrophoresis Chambers Gibco BRL Horizontal Gel Electrophoresis 
Apparatus 
Micropipettes Gilson 
Microwave Whirlpool 
Light Microscopes Leica Labovert FS, Nikon TMS 
Epifluorescent Microscopes AxioVision, Carl Zeiss 
PCR Machine T3 Thermocycler, Biometra 
pH meter Beckman 
Photometer Nanodrop Spectrophotometer, Peqlab 
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Power Supplies Gibco BRL 
 Phero-stab, Bachofer 
 Biorad Power Pac 
 Desaga Mains Power supply unit 
Precision Weighing Sartorius 
Shaker Heidolph 
Sterile Work Benches Steril Gard Class II Type A/B3, Baker Company 
Hersafe, Heraus 
Table Top Centrifuges Eppendorf 
 HeraeusBiofuge 
 Heraeus Christ Minifuge GL 
 HettichRontana/S 
Thermomixer Eppendorf 
U.V Chamber Hanau 
Vortex Scientific Industries Vortex Genie 2 
Water Bath GFL                          
Table3:Summary of equipments used 
 
 
2.1.2 Consumables 
 
Table 4:Summary of consumables 
 
 
Material Supplier 
Bacterial Petri dishes Nunc 
Cell culture plates (96 well, 48 wells, 24 wells, 12 wells, 6 
wells) Nunc, Corning 
CombiTips (0.5ml, 1.25ml, 2.0ml, 2.5ml, 5 ml) Eppendorf 
Cryogenic Vials Corning 
F/AIR Filters Rothacher Medicals 
Falcon tubes (15, 50 ml) Greiner bio-one 
PCR tubes Biozym 
Pipette tips (20μl, 200μl, 1000μl) Star Labs 
Safe Lock Tubes (1.5ml, 2.0ml) Eppendorf 
Syringe Filters (0.2μM and 0.45μM) Sartorius 
Syringes (1 ml, 5 ml, 20 ml) Omnifix® 
Tissue Culture dishes Corning, Greiner Bio-one 
MicroAmp® Optical 96-Well Reaction Plate Life Technologies 
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2.1.3 Chemicals& Kits 
. 
 Table5: Summary of chemical reagents and kits used 
 
 
 
 
 
 
 
Chemicals Supplier Catalogue nr. 
Azacytidine  Sigma Aldrich A2385-100MG 
Doxycycline hyclateBioChemica AppliChem GmbH A29951,0025 
Decitabine Sigma Aldrich A3656-10MG 
IsoFlo® Allbrecht GmbH 701-005-301 
10 mMdNTP Mix Invitrogen 18427-013 
2x Red PCR Master Mix p.j.k. 302004 
Sodium butyrate Sigma Aldrich B5887-250MG 
Valproic acid Sigma Aldrich P4543-25G 
EZ DNA methylation Zymo research D5002 
lipofectamine 2000 Lifetechnologies 11668019 
Mini prep Kit (250) Qiagen 27106 
Genomic DNA isolation Qiagen 51306 
SYBR® Green PCR Master Mix Life Technologies 4309155 
Anti H3K4 acetylation Millipore 07-539 
Anti H3K27 trimethylation Millipore 07-449 
Zero blunt cloning kit Life Technologies K2700-20 
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2.2 METHODS 
 
2.2.1 Agarose gel electrophoresis 
 
For mixing a 1% gel, 1g of agarose was dissolved in 100ml 1 x TAE (40mM Tris/acetate pH 
7.5,20mM NaOAc, 1mM EDTA) by boiling in a microwave. After relative cooling 1μl of 
ethidiumbromide (10mg/ml) was added and mixed while casting onto gel tray. After the gel 
solidified itwas transferred to an electrophoresis chamber filled with 1 x TAE. DNA samples 
were mixedwith 5 x loading buffer (15% Ficoll, 50mM EDTA, 1xTAE, 0.05% Bromophenol 
blue, 0.05%Xylenecyanole) and loaded to the gel. For the determination of the size of DNA 
fragments, amarker was loaded in parallel (Hyperladder I, Bioline). Electrophoresis was 
performed at 80-100V and 30mA. Gels were examined under UV-light (360nm). 
 
2.2.2 Restriction analysis 
 
For digesting DNA, restriction endonucleases were used following the reaction 
conditions(buffers and temperatures) as specified by the manufacturer (NEB). 
 
2.2.3 Mammalian cell culture and mice 
 
Cells used and culture conditions 
 
HEK293T cells (ATCC CRL-11268) and CHOK1cells (ATCC CCL61) were cultivated at 37°C in a 
humidified atmosphere with 5% CO2. The human cell line was maintained in DMEM (GIBCO, 
Carlsbad, CA). For the CHOK1 cell line we used DMEM medium and Ham´s-F12 medium 
(Invitrogen) in a ratio of 1:1. Culture media were supplemented with 10% fetal calf serum, 2 
mM L-glutamine, Penicillin (10 U/ml) and streptomycin sulfate (100 µg/ml). 
Targeted murine embryonic stems cells obtained from U. Hillebrand  done with pEM-
rTA2luc3eGFP vector (99) and cultured in the standard cell culture medium used for murine 
embryonic stem cells( mES cells) was composed of KnockoutTM DMEM optimized for ES cells 
(GIBCO) basal medium supplemented with 15% Heat-Inactivated FBS (SIGMA), 1x Glutamax, 
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1x Na Pyruvate, 1x non-essential amino acids, 1x Pen/Strep, ß-mercaptoethanol, and 
leukemia inhibitory factor (LIF). 
 
Mice 
 
Targeted murine embryonic stems cellswith pEM-rTA2luc3eGFP vector (99) were used to 
generate transgenic mice. This mouse line was called RosaGFPand was maintained in the 
breeding facilities of Helmholtz Centre for Infection Research (HZI, Braunschweig, Germany). 
All the experiments were carried out in accordance with the ethical board approval and 
guidelines. The mice were housed in isolated ventilated cages in the mouse house facility of 
the institute. 
 
Vectors used in the study 
 
Newly cloned Vectors 
 
1) pTAG CMVGFP(pLVsspwv) 
The lentiviral self-inactivating tagging vector (pTAG CMV GFP) was derived from 
pJSARGFP(114). The lentiviral SIN backbone of pJSARGFP (ClaI-NheI fragment) comprising 
the LTRs, REV responsive element and woodchuck hepatitis regulatory element (WPRE) was 
ligated to a reporter cassette comprising the CMV promoter driving eGFP reporter gene. 
This cassette was further flanked by a set of heterospecific, non-interacting Flp 
recombination-target sites FRT-WT and FRT-F5. 
 
2) pEM-OCGrtTA2luc3eGFP(CpG free BiTet with dual marker-Luciferase and eGFP) 
The CpG free bidirectional Tet promoter was synthesized from GeneArt with Xho1 and 
ECOR1 restriction sites which were used to clone this CpG free promoter fragment into the 
pEM-rtTA2luc3eGFP vector to obtain a CpG free bitet promoter targeting vector. 
Summary of all the vectors along with their internal database reference bacterial 
number(B.Nr) and DNA number(DNA.Nr) is summarized in the table 3 below. 
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Table 6: Summary of all the vectors used in the present study. 
 
2.2.4 Lentiviral gene transfer 
 
HEK293T cells were used for lentivirus production as specified in Norton et al (109). Briefly, 
HEK293T cells were transfected using the calcium phosphate method with four different 
plasmid constructs: the tagging vector (pTAG CMV GFP), envelope-encoding plasmid 
(pLP-VSVG), gag/pol helper plasmid (pLP1) and REV expressing plasmid (pLP2). After 12 
hours the medium was changed.48 hours after transfection the supernatant containing the 
lentiviral particles was harvested and filtered through a 45 µm filter. The virus supernatant 
was titered by infecting 293T cells with serial dilutions and subsequent flow cytometric 
evaluation. For generation of single copy tagged clones, 1 x 105 HEK293T or CHOK1cells 
were seeded and infected with 1000 viruses (MOI 0.01) in the presence of 8 µg/ml 
protamine sulphate (Sigma Aldrich). The day after infection, medium was exchanged.  
 
2.2.5 Recombinase mediated cassette exchange (RMCE) 
 
Targeting of the tagged clones was done by Flp mediated recombinase cassette exchange 
according to previously published protocols (116). Briefly, the FLPe expression vector 
pFlpe(116) was cotransfected with the targeting vectors pTAR CMV RFP and pTAR SV40 RFP, 
S.NO Name B.Nr Source or references 
1 pEM-rtTA2luc3eGFP B6272 (97). 
2 pCMVRTA2HYG B6321 This study 
3 pTAR CMV-RFP B6844 (115). 
4 PTAR SV40-RFP B6589 (115). 
5 pTAG CMV GFP(pZLE-1)) B7023 This study 
6 pEM-OCGrtTA2luc3eGFP B7713 This study 
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respectively, using lipofectamine 2000 (Life technologies) in a molar ratio of 3:1 according to 
manufacturer’s protocol. Media was exchanged after 5 hours. 10 days after transfection, the 
cells were sorted for lack of GFP expression resulting from successful RMCE. Targeted vector 
integration was confirmed by PCR.  
 
For mES cell targeting, 1 x 104were seeded in the 6 well plate without feeders and the FLPe 
expression vector pFlpe(116)werecotransfected with the targeting vectorspEM-
rTA2luc3eGFP(99) and CpG free pEM-oCGrTA2luc3eGFP, respectively, using lipofectamine 
2000 (Life technologies) in a molar ratio of 3:1 according to manufacturer’s protocol(99). 
Briefly, media was exchanged after 5 hours. After 48 h post transfection, the transfected ES 
cells were transferred to feeder coated 10 cm cell-culture dishes and selection pressure with 
G418 at a concentration of 0.4 mg/ml was applied. As a negative control, untransfected mES 
cells and mES cells transfected with only the Flp recombinase expression plasmid was 
always included. Selection was usually carried out for 8–10 days during which it was 
ascertained that all the cells in the negative control were killed. Putative RMCE targeted 
G418 resistant subclones obtained were then picked and analyzed for GFP expression 
2.2.6 Chemical treatments 
 
For the chemical treatments 1 x 105 cells were seeded in a 24-well plate format. HDAC 
inhibitors sodium butyrate (Sigma Aldrich) and Valproic acid (Sigma Aldrich) were dissolved 
in PBS and added at a final molecular concentration of 1µM and 300mM, respectively. 
For treatment of mES cells,1 x 105 cells were seeded in a 12-well plate format. Dnmt 
inhibitors azacytidine (Sigma Aldrich) and Decitabine (Sigma Aldrich) were dissolved in PBS 
and added at a final molecular concentration of 1µMand 0.5µM, respectively. 
Treated and untreated control cells were cultivated for 72 hours and then harvested for 
further analysis 
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2.2.7 Flow cytometry 
 
Flow cytometry was used for the analysis of transgene expression with BD FACScalibur. 
Sorting of the cells was done with FACSaria, FACScanto, using appropriate laser and ﬁlter 
settings for GFP and RFP, respectively. A gating strategy was used to eliminate doublets and 
dead cells or debris. Results were quantiﬁed with the FlowJo 7.6 software. 
2.2.8 Chromatin Immunoprecipitation (ChIP) 
 
Chromatin immunoprecipitation was done using the ChIP-IT High sensitivity Kit (Active 
Motif). The protocol was followed according to the manufacturer’s instructions. Briefly, 
about 1,5 x 107 cells were fixed and their chromatin was sheared upon sonication. Sonicated 
samples were incubated at 4°C overnight with specific antibodies against H3K27me3 
(Millipore, cat.no-07-449) and H3K4ac (Millipore, cat.no-07-53907-53907-539D07-
539DEdddd07-539) (,6μg/reaction). Immunoprecipitation was done using Protein G agarose 
beads. Finally the DNA was purified after the reversal of crosslinks and subjected to 
quantitative PCR.  
For quantitative PCR the following primers were used for the CMV promoter region 
(forward primer 5’-AAGTACGCCCCCTATTGACG-3’ and reverse primer 5’-
AAACCGCTATCCACGCCCAT-3’. PCR conditions were as follows: 10μl SYBR green RT-PCR mix 
(Qiagen), 1μl (10mM) forward primer, 1μl (10mM) reverse primer, 8μl immunoprecipitated 
DNA. Real-time PCR was performed on a LightCycler 480 apparatus (Roche). The reagents, 
primers and samples were added in a 96-well-plate (Roche). All assays were performed in 
triplicates. The reaction was performed according to the following conditions: 1. Pre 
incubation: 95°C 15min. 2. Amplification: a. Denaturation 95°C for 15 sec. b. Annealing 58°C 
20 sec. c. Elongation 72°C 30 sec (45 cycles). 3. Melting curve a.95°C 5 sec.b.70°C 1min 
c.95°C continuously.4. Cooling 40°C 30 sec. 
Percentage input was used to quantify the enrichment.With this method, signals obtained 
from the ChIP are divided by signals obtained from an input sample prepared separately 
according to the manufacturer protocol. One percent of the input was taken(1:100 diluted) 
and calculated accordingly with final adjustment of 6.64 being subtracted from the 1% input 
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Ct value ( if the starting input fraction is 1%, then a dilution factor (DF) of 100 or 6.644 cycles 
(i.e., log2 of 100) is subtracted from the Ct value of diluted input). 
2.2.9 Bisulfite Sequencing 
 
A) Determination of methylated cytosines using Epitypher(adapted from the lab of 
Prof. Dr. M Rehli)  
A common method for analyzing cytosine methylation is bisulfite conversion of DNA 
followed by sequencing. Cytosine-derivates undergo reversible reactions with bisulfite 
yielding a 5,6-Dihydro-6-sulfonate, which deaminates spontaneously. After that the sulfate 
is eliminated under alkaline conditions, leaving uracil. 5’-methyl cytosine is not affected by 
this reaction and so unmethylatedcytosine appears as a Uracil in the sequencing reaction 
whereas 5’-methyl cytosine remains cytosine.  
In the following procedure this methylation specific difference is used for generating 
methylation depending mass differences that areanalysed by mass spectrometry. All 
reagents in this section were obtained from the EZ DNA methylation kit (Zymo). 1 μg of 
genomic DNA was brought to a volume of 45 μl and was diluted with 5 μl M-Dilution Buffer, 
mixed and incubated at 37°C for 15 minutes. After incubation 100 μl of CT Conversion 
Reagent was added, lightly vortexed and incubated in the lightcycler with the following 
protocol: 
Step 1:  95°C  30 sec  
Step 2:  50°C  15 min  
Step 3:  Repeat steps 1-2 for 20 cycles  
Step 4:  4°C  hold  
 
Afterwards the samples were incubated on ice for 10 minutes, 400 μl of M-Binding Buffer 
was added and the sample was loaded on a Zymo-Spin I Column placed in a 2 ml collection 
tube. DNA was bound by centrifuging at full speed for 15-30 seconds, washed with 200 μl 
M-Wash Buffer, centrifuged again for 15-30 seconds and then treated with 200 μl M-
Desulfonation Buffer for 15 minutes at room temperature. After incubation the column was 
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centrifuged for 15-30 seconds, washed twice with 200 μl M-Wash Buffer centrifuging 30 
seconds and 1 minute respectively at full speed to remove wash buffer residues. To elute 
the DNA 100 μl water was added directly to the centre of the column and centrifuged 30 
seconds at 3000 rpm. The procedure yields 100 μl of bisulfite converted DNA with a 
concentration of 7-8 ng/μl. 
 
 
PCR-amplification  
 
Polymerase Chain Reaction (PCR) allows the specific amplification of DNA segments (see 
4.2.1). The PCR-reactions were prepared in 384 well plates (ABgene) with the following 
reagents according to the manufacturer 
Component  Volume for single 
reaction  
Final concentration  
ddH2O  1.42 μl N/A  
10x HotStarBuffer 0.5 μl 1x  
dNTP mix 25 mM each  0.04 μl 200 μM 
5 U/μl Hot Star Taq 0.04 ml  0.2 U  
DNA Template  1 μl 5-10 ng  
 
To each reaction 2 μl primer mix was added, giving a final reaction volume of 5 μl, with the 
concentration of 500 pM of the forward and reverse primer. Then the plate was sealed with 
AB-0558 spun down, centrifuged and incubated in a Veriti 384 well thermal cycler (Applied 
Biosystems) with the following programme: 
Step  Temperature  Time  Cycle  
Initial 
denaturation  
94°C  4 min  1  
Denaturation  
Annealing  
94°C  
59°C  
20 sec  
30 sec  
45  
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Elongation  72°C  1 min  
Final elongation  72°C  3 min  1  
Cooling  4°C  hold  1  
 
Shrimp Alkaline Phosphatase (SAP) Treatment  
 
Unincorporated nucleotides can disturb downstream applications and are therefore 
enzymatically inactivated. Under alkaline conditions SAP removes phosphate groups from 
several substrates including deoxynucleotide triphosphates, rendering it unavailable for 
further polymerase catalyzed reactions. The SAP solution was prepared as follows: 
Component  Volume for single 
reaction  
RNAse free water  1,7 μl 
SAP  0.3 μl 
2 μl of the SAP solution was added to each PCR-reaction with the 96 channel pippeting 
robot MassARRAY Liquid Handler and FusioTM Chip Module (Matrix). The plate was sealed 
with AB-0558, centrifuged and incubated as follows on a Veriti 384 well thermal cycler 
(Applied Biosystems): 
Step 1:  37°C  20 min  
Step 2:  85°C  5 min  
Step 3:  4°C  hold  
 
 
In vitro transcription and RNaseA treatment  
 
The PCR reaction is transcribed into RNA in vitro with the T7 RNA polymerase, which is 
guided to the amplified PCR-products by the introduced T7 promoter tag in the reverse 
primer. The transcribed RNA is in the same reaction enzymatically cleaved by RNaseA, 
cleaving specifically after cytosine and thymine. T-specific cleavage is achieved by using 
modified cytosine triphosphate nucleotides which protect from RNaseA digestion when 
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incorporated in an RNA polymer. The RNase and T-cleavage mix was prepared according to 
the manufacturer’s instruction: 
Component  Volume for single reaction  
RNase free water  3.21 μl 
5x T7 Polymerase buffer  0.89 μl 
Cleavage Mix (T mix)  0.22 μl 
DTT (100 mM)  0.22 μl 
T7 R&DNA Polymerase (50 U/μl)  0.4 μl 
RNase A  0.06 μl 
Total volume  5 μl 
 
60 5 μl of the mix and 2μl of the SAP treated PCR reaction were transferred into a new 386-
well plate with the 96 channel pippeting robot MassARRAY Liquid Handler and FusioTM Chip 
Module (Matrix), sealed with AB-0558, centrifuged and incubated on a Veriti 384 well 
thermocycler C (Applied Biosystems) for three hours at 37°C.  
 
Desalting of cleavage reaction: resin treatment  
 
Because salt ions are co-vaporised when acquired during MALDI-TOF analysis they are 
therefore visible in the mass-spectra. This would irritate the analysis of the mass-spectra 
and therefore the reactions need to be desalted. For desalting of the transcription/cleavage 
mix 20 μl water was added to each reaction with the MassARRAY Liquid Handler (Matrix) 
followed by the addition of 6 mg CLEAN resin per reaction. This mix was rotated for slowly 
for 10 minutes and spun down to collect the resin at the bottom of the wells.  
 
 Transfer on SpectroCHIP and acquisition  
 
The SpectroCHIP holds the matrix on which the sample probes are spotted and consists of a 
crystallized acidic compound. When the analyte is spotted on the matrix its solvent dissolves 
the matrix, and when the solvent evaporates the matrix recrystallizes with analyte-
molecules spread enclosed in the crystals. The DNA samples are transferred on a 
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SpectroCHIP with the Phusio Chip Module and analysed with the MassARRAY Compact 
System MALDI-TOF MS (all Sequenom). The co-crystallized analyte is acquired with a laser 
while the matrix is predominantly ionized, protecting the DNA from the disruptive laser 
beam. Eventually the charge is transferred to the sample and charged ions are created 
which are accelerated in a vacuum towards a detector that measures the particle’s time of 
flight.  
 
 
 
Data processing  
 
Acquired data was processed with the EpiTyper Analyzer software (version 1.0.5, 
Sequenom). The MS is calibrated with a four point calibrant (Sequenom) containing 1479, 
3004, 5044.4 and 8486.6 kDa particles. Relative to this calibration the accelerated analytes 
generate signal intensity (y-axis) versus mass (kDa, x-axis) plots. With the sequence of every 
amplicon known, the software can virtually process the sequence and predict the fragments 
from the in vitro transcription/RNase digestion and relocate CpG units. If fragments contain 
a single CpG this is called a CpG-site. More CpG-sites within one fragment are summarized 
to a CpG-unit get a sum methylation value since the software averages the methylation of 
the individual CpG-sites. If expected and incoming information match, the signal intensities 
of the methylated and unmethylated DNA templates are compared and quantified. A 
normal calibrated system is able to measure fragments between a range of 1500 and 7000 
Dalton. Fragments outside of this range and fragments whose mass peaks are overlapping 
with multiple other fragments cannot be analysed 
B) DNA methylation analysis by cloning and sequencing  
All reagents were obtained from the EZ DNA methylation kit (Zymo). The protocol was 
followed according to the manufacturer’s instructions. Bisulfite converted DNA was 
amplified with bisulfite primers specific for CMV promoter (forward primer 5’-
GTATATGATTTTATGGGATTTTTTTATTTG-3’ and reverse primer 5’-
ATTCACTAAACCAACTCTACTTATATAAAC-3’). The reaction was performed on PCR machine 
(Biometra) according to the following conditions: 1. Pre incubation: 95°C 15min. 2. 
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Amplification: a. Denaturation 95°C for 30 sec. b. Annealing 55°C 60 sec. c. Elongation 72°C 
60 sec (45 cycles). 3. Final elongation 72°C 7min.  4. Final hold 4°C. Amplified PCR products 
were integrated into the PCR blunt cloning vector (Invitrogen) using the protocol according 
to the manufacturer’s instructions. Upon transformation, single independent clones were 
picked and expanded. Plasmid DNA was isolated, purified and sequenced (HZI sequencing 
facility). Sequences were then analysed for the presence of C to T conversions indicating 
unmethylatedCpGs. 
 
2.2.10 Bioluminescence imaging with Xenogen IVIS 200 (for luciferase expression in 
mice) 
 
To monitor the luciferase/bioluminescence activity of injected cells in a particular animal 
repeatedly without the need for sacrificing the animal the in vivo imaging technology 
(Xenogen/Caliper).  Initially, a grey-scale image of the sample in the light tight chamber was 
automatically taken. Then, photons were collected by a sensitive CCD camera and the 
signals were overlaid to the grey-scale image.  Parameters such as the aperture of the 
lenses, exposure time and binning are adjusted so as to regulate the sensitivity and 
resolution of the image.  The field of view was adjusted to obtain images of up to 5 mice in 
one round. Analyses of images were performed with the Living image 2.60.1 (Igor Pro 4.09A) 
computer programme.  Animals were first anaesthetized in the induction chamber by 2-
2.5% isoflurane (Albrecht). Mice were then injected intra-peritoneal with 100μl of luciferin 
(30mg/ml in PBS, Synchem OHG) and placed on the heated (37°) platform in the acquisition 
chamber.  Anaesthesia was maintained by constant administration of isoflurane via nose 
cones while images were taken. All the images acquired were analysed using the Living 
Image 2.60.1 (Igor Pro 4.09A) software. 
 
2.2.11Luciferase expression in vitro culture 
1 million cells were washed with PBS and were suspended in 500μl 1X RLB buffer 
(Promomega) and were frozen in -20 C for 20 minutes. These cells were then thawed and 
20μl of the supernatant was mixed with 100ul of the Luciferase Assay Reagent into 
luminometer tubes, luminance was then quantified. Final quantification involved the basal 
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correction where the expression from the cell line without the luciferase was subtracted 
from test samples. Further, the expression was related to the total amount of protein 
quantified using Bradford assay. 
2.2.12 Computerprograms and software analysis 
 
This thesis was written using the Microsoft Office 2010 package specifically Microsoft Word, 
PowerPoint, Picture Manager and Excel.  Flow cytometry results were analysed with either 
the CellQuest Pro program or FlowJo version 10. RT-PCR reactions were analysed either by 
Microsoft Excel or with the LightCycler 480 SW1.5 Software and Microsoft Excel.  Graphs 
were generated either using Microsoft Excel or GraphPad Prism software.  In vivo 
bioluminescence data was analyzed with the Living Image 2.60.1 software from Xenogen. 
Microscopic images were analysed with ImageJ software. 
2.2.13 Histological sections 
 
Mice were sacrificed and tissues from different organs were fixed for 48 hours in Formalin 
and then dehydrated in 70% ethanol before processing for GFP staining by the 
histopathology facility of the HZI.  The analysis of GFP and micrograph preparation was 
performed by Dr. Marina Pils and Dr. KatrinSchlarmann of the Histopathology Facility of the 
HZI.    
 
2.2.14 Statistical evaluation 
 
Statistical analyses were performed using GraphPad Prism 5.0 software (GraphPad, 
SanDiego,CA). Data between two experimental groups were analyzed using Mann-Whitney 
test. The differences were considered as statistically significant if p<0.05(*), p<0.01(**), 
p<0.001(***). 
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3 RESULTS 
 
The thesis comprises two different approaches to elucidate the crosstalk of transgene 
cassettes with the chromosomal environment of the integration site. In the first part of the 
Result section (3.1), a conventional screening approach relying on random transgene 
integration is used to identify clones with high transgene expression levels. 
In the second part of the Result (3.2), the focus will shift to the specific crosstalk observed 
upon targeted integration of transgene cassettes into a previously identified chromosomal 
site. 
3.1. Crosstalk of transgene expression cassettes in randomly obtained sites 
in HEK293T cells and CHOK1 cells 
 
3.1.1 Tagging of genomic loci with FRT sites using lentiviral transduction 
 
In order to identify chromosomal sites that support transgene expression, a screening 
cassette with GFP reporter gene driven by CMV promoter was randomly integrated into the 
genome of CHOK1 cells and HEK293T cells. The overall outline of the strategy is presented in 
Fig 6. As a reliable method for achieving single copy integrations lentiviral transduction was 
used. A self-inactivating (SIN) lentiviral vector with a deletion of the viral promoter in the 
3’LTR was employed to avoid interference of the viral regulatory elements with the CMV 
promoter upon infection (Figure 6). In addition, the reporter cassette was flanked with a set 
of heterologous FRT sites (FRT-WT and FRT-F5) which provides the option for subsequent 
exchange of cassettes by Flp recombinase mediated cassette exchange (108,117). To ensure 
a single copy integration of the screening cassette, infection was performed at a multiplicity 
of infection (MOI) of 0.01. Thereby, statistically, 99% of infected cells carry a single copy 
integration of the expression cassette. 10 days after lentiviral infection cells showing high 
GFP expression (>103 arbitrary units, a.u.) were isolated by single cell sorting (Figure 6). 
Individual cell clones were established in 96 well plates and expanded for further analysis.  
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Figure 6: Strategy for generation of single copy transgene expressing clones. A lentiviral SIN vector 
was used to transfer a CMV driven GFP expression cassette flanked by non-interacting FRT-WT and 
FRT-F5 sites. The lentiviral vector and the proviral state after lentiviral infection and subsequent 
integration into the chromosome are depicted. The figure depicts a representative flow cytometry 
plot obtained of HEK293T cells at day 10 after infection at a multiplicity of infection (MOI) of 0.01. 
High GFP expressing cells were sorted in a single cell/well in a 96 well plates and expanded to derive 
clonal populations that were analysed further for GFP expression at passage 2. 
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3.1.2 Expression analysis of CMV-GFP in HEK293T and CHOK1 clones 
 
The cell clones from both HEK293T and CHOK1 were established and then individual clones 
from the two cell lines were randomly picked and expanded. In total 55 clones from 
HEK293T and 60 clones from CHOK1 were analysed for GFP expression using flow 
cytometry. Interestingly, the analysis of the clonal population from both the cell lines 
showed varying GFP expression levels (Fig. 7 shows representative clones for HEK293T cells; 
See also Fig. XX for an overview of all the clones analyzed). 
Although these clones were sorted for high GFP expression (>103a.u), most of the clones 
showed an overall decrease in the expression levels in both the cell lines. The clonal 
populations varied significantly in spite of arising from cells that were sorted for similar 
expression (>103a.u).  
Another interesting observation was the large variance in the clonal population of both the 
cell lines. Most of the clones had cell fractions that showed significant reduction in 
expression and also loss of expression. Clones like 02, 06, 31, 42, 44 and 54 in Fig 7 showed 
this large variance with distinct cell populations in both expressing (>101 a.u) and non-
expressing (<101a.u). The clones that showed nearly 10% cell populations losing the 
expression below (103a.u) were characterized as heterogeneous while the clones that had 
major percentage (>90%) of cells still expressing in excess of 103a.u were classified as 
homogeneous.  
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Figure 7: Expression profiles of HEK293T cell clones 2 passages after initial sortingaccording to Fig 6. 
FACS plots show the GFP expression profiles of indicated HEK293T clones.Clones from HEK293T with 
homogenous expression (>90% expressing in excess of 10
3
a.u) are highlighted with blue circle and 
heterogeneous marked by yellow rectangle(clones where nearly 10% of cell fraction shifted below 
10
3
a.u). 
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3.1.3 Intraclonal variation in HEK293T and CHOK1 cell clones 
 
The 55 clones from HEK293T and 60 clones from CHOK1 were categorized with respect to 
the mean fluorescence intensity (MFI) of the overall population as well as the percentage of 
cells providing high (>103a.u.), low (103 -101 a.u.) and no GFP expression (<101 a.u).  
The results for HEK293T cells and CHOK1 cells are summarized in Figure 8 and 9, 
respectively. Although the initial sorting was restricted to cells that show >103a.u., in the 
established clones only about 10% (6/55) of the HEK293T clones showed homogenous and 
high GFP expression with >90% of high GFP expressing cells with an MFI > 2000 a.u. (marked 
by * in Figure 8).  
In contrast, none of the CHOK1 clones provided homogenous and high GFP expression. This 
suggests cell type specific differences in the inactivation of transgene expression. Most of 
the CHOK1 clones (88%) and also 15% of the HEK293T cell clones (8/55) showed a significant 
drop of expression below an MFI of 1000 a.u. (Figure 9). In general, the overall expression 
level was higher in HEK293T clones in comparison to clones derived from CHOK1 cells. Three 
CHOK1 clones (12, 53 and 60) showed no GFP expression (Figure 9).  
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Figure 8: Summary of the GFP analysis (% expressing cell populations and mean fluorescent intensity 
(MFI)) in 55 randomly selected HEK293T clones. Three colours in a bar represent three populations 
within a clone classified according to transgene expression levels (blue <10
1
, red-10
1
-10
3
, green >10
3
). 
The blue line represents the MFI of 1000 a.u..The HEK293T clones that showed homogenous and high 
GFP expression with >90% of high GFP expressing cells with an MFI > 2000a.u. (marked by *). 
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 RESULTS 
44 
 
 
Figure 9: Summary of the GFP analysis (% expressing cell populations and mean fluorescent intensity 
(MFI)) in 60 randomly selected CHO clones. Three colours in a bar represent three populations within 
a clone classified according to transgene expression levels (blue <10
1
, red 10
1
-10
3
, green >10
3
). The 
blue line represents the MFI of 1000 a.u. 
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The heterogeneous expression of GFP suggested that transgene expression changed within 
the first days of cultivation/passaging. To analyze the underlying mechanism five cell clones 
12T, 17T, 31T, 42T and 54T from HEK293T cells with different patterns of heterogeneity were 
selected for in depth elucidation of the underlying mechanism (see Figure 7 for the specific 
expression pattern of these clones). While clone 12T and 17T showed a distinct GFP 
expression profile, the other three clones were characterized by highly heterogeneous 
expression profiles with high intraclonal variations (Figure 7). In all of the clones a small but 
distinct population of non-expressing cells was detected.  
The GFP expressing and GFP non-expressing cells of these five clonal populations were 
sorted at passage 3. After sorting, the GFP expressing and non-expressing populations, 
called PS and NS respectively, were expanded. To investigate if this loss of GFP expression 
was due to loss of the transgene cassette the chromosomal DNA was isolated from the NS 
cell fraction of HEK293T cell clones and also from the completely silenced CHO clones (#12, 
53, 60 see Figure 9). A PCR was performed using primers (P1 and P2) binding to CMV 
promoter region of the transgene. Clones with transgene integration were expected to give 
rise to a 283 bp fragment (Figure 10). 
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Figure10: Normal PCR for confirming the integration of transgene in the negative sorted (NS) HEK293T 
clonal fractions with no GFP expression and three uniformly silenced clones in CHO cells. Primer pairs 
P1 and P2 were used that amplified a region of 280bp in the CMV promoter region of the transgene 
as indicated. 
 
Although heterogeneous, but none of the clones completely lost expression in HEK293T cell 
clones. This was in contrast to CHOK1 where 3 clonal populations (12C, 53C, 60C see Figure9) 
showed complete silencing (>99% cell not expressing GFP). Also, the fractions of cells not 
expressing (indicated by blue region in the bar graphs of Figure8 and 9) or low expressing 
(indicated by red region in the bar graphs of Figure8 and 9) were more pronounced in 
CHOK1 derived clones. Henceforth, the statistical evaluation indicates a pronounced 
instability of transgene expression in CHOK1 cells. 
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3.1.4 Heterogeneity in expression is not correlated to CpG methylation in the CMV 
promoter 
 
The CMV promoter – although providing high levels of expression in many cell types – has 
been shown to be sensitive to DNA methylation both in vivo and in vitro (118-120). The 
degree of methylation was found to correlate with the expression status of the cells (121). 
Thus, it was hypothesized that the heterogeneity in transgene expression might be 
modulated by epigenetic modification of the CMV promoter. The DNA methylation status of 
the promoter in the sorted NS and PS populations was analysed (at passage 3). In particular, 
the focus of the analysis was on a 283 bp fragment of the CMV promoter encompassing the 
TATA box and essential transcription factor binding sites as well as 14 CpG sites which could 
be potentially methylated (see Figure 11A).  
To analyze the DNA methylation status of the selected region of CMV promoter, bisulfite 
conversion of genomic DNA was done.Briefly, bisulfite treatment involves treatment of the 
DNA with sodium bisulfite which converts the cytosine into uracil. However, the cytosines 
that are methylated do not undergo this reaction and remain as cytosine. This converted 
DNA is that amplified by PCR using primers specific for the region of interest. PCR 
amplification leads to copying of uracils as thymine. The PCR products are cloned and then 
sequenced. The non-methylated cytosines are read as thymines whereas methylated 
cytosine remains cytosine. 
Upon conversion of the DNA of the various cell populations, the CMV promoter fragment 
was amplified by PCR and integrated into a cloning vector and transformed in E. coli. From 
each HEK293T cell population eight bacterial clones were randomly picked and sequenced. 
Thus, the sequences reflect the methylation status of the CMV promoter in eight 
individual/single HEK293T cells. 
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Figure11: Methylation analysis of the CMV promoter. A) The sequence of the CMV promoter region 
used for methylation analysis. PCR primer binding sites are indicated by arrows (P1 and P2). The 
transcription factor and their binding sites are labelled and 14 CpG motifs are shown by dotted circle. 
The TATA box is highlighted in yellow. Genomic DNA was isolated from the sorted PS and NS 
populations of HEK293T (B) and 5 CHOK1 (C) clones and subjected to bisulfite conversion. The 
promoter region was amplified by PCR using the primers indicated in A and integrated into a cloning 
vector. Random clones were picked and sequenced. Each circle in a line represents a CpG dinucleotide 
according to the sequence above. The figure shows the sequences from 8 randomly selected clones 
per cell line reflecting independent single cells. Unfilled circle represent non methylated CpG 
dinucleotides and black filled circles represent methylated CpG dinucleotides..D) Analysis of NS 
population of clone12
T
, 17
T
, and 54
T
 after 40 passages. 
 
None of the clonal population showed any methylated CpG in the GFP expressing cell 
fractions. This was as expected since promoter methylation is mostly associated with 
silencing and thus it should be absent in cells that express the transgene (Figure 11B). 
However, contrary to expectations, sequencing of the clones from the cell populations that 
completely lost GFP expression (non-GFP expressing populations of clones 12T, 17T and 54T; 
Figure 11B)revealed complete absence or rarely methylated CpGs (Figure 11B). Statistical 
analysis revealed that less than 0.5% of the analyzed CpG motifs in the CMV promoter 
fragment were found to be methylated. Thus, in none of the cell populations a significant 
number of methylated CpGs was observed.  
 
To evaluate whether such a stable silencing without DNA methylation is a cell line 
dependent phenomenon or whether it is a more general mechanism adopted by the cells, 
analysis of representative clones derived from CHOK1 cells was also done. This included 
clone 12C and clone 60C (in which GFP expression rapidly dropped within the first two 
passages) and clones 9C, 10C, and 55C with a heterogeneous expression pattern. 
Interestingly, in none of the CHOK1 clones methylation of CpGs played a major role (Figure 
11C). Interestingly, also none of the clones from CHOK1 showed differential methylation 
pattern again contrary to what was expected since CHO 5 clones   
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To investigate if the methylation frequency would increase during cultivation the 
methylation status in these clones was also analysed after 40 passages post sorting. 
Importantly, also at this late time point both the expressing and non-expressing cells 
remained largely free of CMV promoter methylation (Figure 11D). This excludes a delayed 
manifestation of DNA methylation upon prolonged passaging as was previously suggested 
for other experimental settings (122-124).  
Together, these results clearly show that silencing of gene expression in HEK293T cells and 
CHOK1 was not reflected by methylation of the CMV promoter. From these results it can be 
concluded that DNA methylation of the CMV promoter does neither cause nor correlate 
with the phenotypic heterogeneity and is thus not involved in silencing of CMV driven GFP 
expression in the HEK293T and CHOK1 derived cell clones.  
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3.1.5 High GFP expression correlates to differential levels of active and repressive 
histone markings 
 
Since DNA methylation could be excluded to be the underlying mechanism of transgene 
silencing further analysis focused on the abundance of histone modifications in the sorted 
populations of the 5 selected clones. For this purpose chromatin immunoprecipitation 
(ChIP) was done. Briefly, in ChIP protein-DNA complexes are cross-linked, 
immunoprecipitated, purified, and amplified for gene- and promoter-specific analysis of 
known targets using real time PCR. The calculation of the enrichment is done through the 
‘percent input’ method.With this method, signals obtained from the ChIP are divided by 
signals obtained from an input sample. This input sample represents the amount of 
chromatin used in the ChIP.  
 
 
 
Figure12: Analysis of differential histone modifications in GFP expressing and non-expressing 
subpopulations. Chromatin immunoprecipitation (ChIP) was performed for the sorted PS and NS 
fractions from the five HEK293T clones using antibodies against H3K4 acetylation and Histone H3 
lysine 27 trimethylation. The precipitated fractions were subjected to real time PCR. The 
quantification was done relative to percent input as described in the text and in the Material and 
Methods section. The graphs represent the mean from 3 separate ChIP experiments. 
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The acetylation of lysine 4 marking on histone H3 (H3K4ac) was evaluated using ChIP. 
H3K4ac has been described as a marker of open chromatin, which isassociated with 
transcriptionally active areas (125). Interestingly, the cell populations of the five clones 
displayed a differential pattern of histone modifications. The PS populations sorted for GFP 
expression were enriched for the H3K4ac marking. In contrast, the GFP negative NS 
population showed these H3K4ac marks with much less frequency (Figure 12). This indicates 
that GFP expression correlates with elevated levels of H3K4ac.  
Since the differential pattern of acetylation was observed, another question was if there 
were other repressive differential histones marking also present with respect. To analyze 
this ChIP analysis was performed for trimethylation of lysine 27 on the histone H3 
(H3K27me3) known to mediate DNA methylation. independent transcriptional suppression 
and is  also held to be responsible for stabilizing the silencing phenotype (126). Following a 
ChIP analysis with a specific promoter according to the strategy described above, a strong 
enrichment of the H3K27me3 marking in the CMV promoter of the NS populations of all 
clones was observed. In contrast the PS population with GFP expressing cells showed lower 
frequency of this modification (Figure 12).  
These results showed that the phenotypic expression patterns of the sorted populations 
correlate with a differential histone modification pattern. 
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3.1.6 Activation of transgene expression upon treatment with epigenetic modifiers 
 
Since histone modifications were the major cause of silencing of the CMV promoter in the 
clonal populations, it was speculated that treatment of non-expressing cell populations with 
inhibitors of histone deacetylation (HDACi) is able to revert the silenced state and to 
increase the transgene expression. For this purposethe cells were cultivated for 72 hrs in 
presence of the HDACi sodium butyrate (NaB) (127) and Valproic acid (VPA) (128,129). Then, 
the expression level was evaluated. 
Interestingly, the five clones responded differentially to the treatment with these drugs. In 
case of clone 31T and 42T these drugs induced a significant increase in the mean fluorescent 
intensity and in the percentage of expressing population (Figure13A).However, there was 
only a slight increase of the mean fluorescence intensity and the percentage of GFP 
expressing cells in the NS population of clone 54T while the NS populations of clones 12T and 
17T did not significantly revert to the expressing state (data not shown). This suggests that 
these populationswere locked in an epigenetically silenced state.  
To confirm that the modification of the expression pattern upon treatment with these drugs 
wasreflected by changes in the histone marks of the CMV promoter we performed a ChIP 
assay for theNaB treated negative sorted populations of clones 31T and 42T. Incubation 
with NaB indeed enrichedthe chromatin with acetylation marking and caused a reduction in 
the H3 trimethylation levels (Figure 13B). 
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Figure13: Stability of histone mediated gene silencing. The indicated cell populations were treated for 
72hrs with histone deacetylation inhibitors Valproic acid prior to analysis of GFP (VPA, blue line) and 
sodium butyrate (NaB, red line). UT indicates untreated controls (black lines). Overall GFP expression 
(left, representative populations), as well as % of GFP expressing cells (middle) and MFI (right) are 
given for 6 independent experiments. B) Treated cell populations were subjected to ChIP analysis for 
H3K4ac and H3K28me3. Graphs represent mean from 3 separate ChIP experiments related to % input 
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3.1.7 Reanalysis of the GFP negative and positive sorted populations 
 
The different population of the five selected clones that were sorted in to GFP negative (NS) 
and GFP positive (PS) were cultured for 25 passages and were then reanalysed for their 
expression phenotype. This was done to analyze the stability of the two phenotypic variants 
from the clonal populations. Also it was be interesting to investigate if the differential 
histone marks can be responsible for stabilizing the silencing and maintain the silenced 
phenotype. 
Interesting, the clones showed a different behaviour. The PS and NS subpopulations of 
clones 12T, 17T and 54T showed a completely stable transgene expression phenotype: the 
GFP positive PS population remained positive and the GFP negative NS population also 
remained negative for GFP (Figure 14).  
In contrast, both of the sorted populations of clones 31T and 42T revealed a highly 
heterogeneous expression pattern upon further cultivation: the NS populations of both 
clones shifted towards higher expression levels while the PS populations showed a partial 
loss of GFP expression. As a result, the respective populations merged upon passaging. This 
suggests that cells can undergo continuous changes from the non-expressing state to the 
expressing state and vice versa, thereby exhibiting a dynamic, “metastable” phenotype. 
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Figure 14: Stability of GFP expression in sorted clonal cell populations: 25 passages after sorting, the 
cell populations were subjected to expression analysis. The composite plots indicate the GFP 
expression of the PS and NS populations of the indicated cell clones 
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3.1.8 Expression profiles upon exchange of expression cassettes through recombinase 
mediated cassette exchange (RMCE) 
 
Chromosomal hot spots of expression can be exploited by targeted integration of expression 
cassettes of choice (95,109,115,130-132). Thereby, it was possible to generate cell clones 
with predictable expression levels of a protein or even recombinant virus of 
interestCoroadinha, Schucht et al. 2006; Schucht, Coroadinha et al. 2006; Nehlsen, Schucht 
et al. 2009;.). So far, however, the chromatin status of the cassette upon exchange was not 
investigated.  Thus, it was of interest to evaluate if the modulation of transgene expression 
at a particular site is a specific feature of the chromosomal locus and would be transferred 
also to incoming ‘naked’ DNA upon targeting. Evaluation was done for this potential in the 
selected GFP expressing cell populations, in particular the PS population of HEK293T clone 
17T as well as CHOK1 clones 9C and 55 C. For this purpose the FRT-WT and FRT-F5 sequences 
were used for integrating a naive expression cassette by recombinase mediated cassette 
exchange (RMCE). 
Three different cassette designs were analysed upon targeting. In the first one the coding 
gene GFP was replaced by RFP while the promoter was kept the same. In the second one a 
CMV based inducible Tet promoter was targeted. Finally, a constitutive, completely 
unrelated promoter (SV40) driving RFP was integrated. The results of these targetings are 
described in the following subchapters. 
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3.1.8a Exchange of the reporter coding gene 
 
First, the cell populations were targeted with an FRT-WT/F5 flanked cassette comprising the 
CMV promoter driving RFP (CMV-RFP, Figure 15A). This would result in exchange of the 
reporter gene but maintenance of the same regulatory sequences. For this purpose the 1 x 
10e5 cells of the respective sorted cell populations (Cl17T, Cl9C and Cl55C) were co-
transfected with a plasmid encoding FlpE recombinase and the CMV-RFP reporter (Figure 
15A). In particular, the FLPe expression vector pFlpe(116) was cotransfected with the 
targeting vectors pTAR CMV RFP (see section… (mat and meth) for details.In this system,Flp 
recombination can give rise to cassette exchange only since the CMV-GFP cassette in the 
isolated clones is flanked by a set of heterologous FRT sites and cannot recombine with each 
other (data not shown). Thus, excision of the GFP cassette is omitted. As a consequence of 
Flp mediated targeting of a CMV-RFP vector, targeted cells would lose GFP expression. Thus, 
excision of the GFP cassette is omitted. As a consequence of Flp mediated targeting of a 
CMV-RFP vector, targeted cells would lose GFP expression. Thus, 10 days after transfection, 
the cells were sorted for lack of GFP expression resulting from successful RMCE.  
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Figure 15: A) Schematic representation of Flp recombinase mediated cassette exchange (RMCE) using 
the vectors pTAR CMV RFP. B) Upon RMCE, for each clone, correctly targeted cells were isolated by 
sorting for loss of GFP expression. Sorted cells were subsequently evaluated for RFP expression by 
flow cytometry.The upper row of FACs plots in Figure 15B represents the parental cells prior to 
targeting and the lower row represents the sorted GFP negative cells after targeting 
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The sorted cell populations were evaluated for fluorescence, RFP after sorting. As expected, 
transfection of the recombinase plasmid pFlpe alone did not alter the percentage of GFP 
expressing cells (data not shown). When analysing the expression upon targeting of the 
clone 17T PS, Cl9C and Cl55Cwith the CMV-RFP vector, nearly all the sorted cells showed a 
high and homogeneous RFP expression, comparable to the GFP expression in the respective 
parental cells (Figure15B). These results show that upon integration of a naked DNA with 
different coding region but with the same promoter, the parental expression phenotype is 
restored. This might indicate to the possibility of that the major contribution in the crosstalk 
between the integration site and transgene might be played by the incoming promoter 
element in the transgene while the coding regions might not be playing that significant a 
role. 
The mechanism of such maintenance of the parental phenotype might lie in the successful 
inheritance of the favorable epigenetic signatures that were present in the parental 
populations and might be the reason of presence of the memory phenotype a observed in 
the above cases. 
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3.1.8b Evaluation of a synthetic promoter construct in HEKCl17PS site 
 
The previous chapter indicated that the clones gave rise to reproducible expression when a 
transgene cassette was introduced with different coding gene but with the same promoter. 
The interesting observation that came out from the above experimental settings was that 
the integration site supported expression of different genes from CMV promoter and these 
integration sites were favorable for transgene expression from CMV promoter in a 
constitutive manner. The CMV promoter has also been used to create the tetracycline 
inducible synthetic inducible Tet promoter (80). Thus, it was evaluated if these 
chromosomal sites are not only supporting constitutive expression from the CMV promoter 
but are also good of inducible expression from CMV derived tetracycline promoter. To 
investigate if the screened sites might also be supporting high, and strictly regulated 
expression from a Tet inducible system based on the minimal CMV promoter, a synthetic 
cassette, pEM-rtT2luc3eGFP(99)having a bidirectional Tet promoter driving GFP and 
luciferase (Figure 16A), was used. To facilitate screening for cassette exchange, this vector 
was targeted into the Cl17PS CMV RFP cells (discussed in Figure15B). 
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Figure 16: A) Schematic representation of Flp recombinase mediated cassette exchange (RMCE) using 
the vector pEM-rtT2luc3eGFP. BUpon RMCE, correctly targeted cells were isolated by sorting for loss 
of RFP expression since the BiTet had GFP as one of the markers so the CL17 with CMV RFP was 
targeted. Sorted cells were evaluated for luciferase expression in the on state and (+Dox) and in an 
un-induced state (-Dox). C) The quantification of GFP expression in on and off state as measured by 
flow cytometry analysis. (Error bars represent the deviation in three independent experiments). D) 
FACS plots showing heterogeneous expression from the BiTet promoter after even 48 hr of induction.  
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Correctly targeted cells were identified and sorted for lack of RFP expression. The generated 
cell populations were then evaluated for luciferase expression upon treatment with Dox. For 
this, cells were kept in presence of Dox (2mg/ml) and as a control without Dox in the culture 
medium. Cell lysates were analyzed for luciferase expression. Also the expression of the GFP 
was also measured through flow cytometry. While the luciferase expression is highly 
sensitive, the GFP expression can be analysed through flow cytometry giving precise single 
cell expression analysis. 
Interestingly, the integration site from Cl 17 PS did support inducible expression from the 
bidirectional Tet promoter after 48 hr of Dox treatment. High luciferase expression 
(>109RLu/μg) (Figure16B) and inducible GFP expression with nearly 80% of cell undergoing 
induction upon Dox treatment (Figure16C) was observed. This was highly interesting and 
contrary to expectation since not only is Tet promoter susceptible to silencing but also if 
targeted in high expressing sites, the regulated expression is generally lost(data not 
shown).However another interesting observation was that even after induction for 48 hr 
there were still about 20 % cells in the population that were not induced. This showed that 
not only in the constitutive CMV promoter, heterogeneity was also evident for CMV derived 
Tet promoter driven construct.  
Therefore, this integration site was not only able to support constitutive expression but was 
also good for inducible expression with induction of nearly 80 % of the total cell population. 
However, the cell to cell heterogeneity still existed even in the transgenes driven by BiTet 
promoter as observed upon single cell analysis through flow cytometry. 
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3.1.8cTargeting a heterologous construct in the tagged loci in HEK293T and CHOK1 cell 
 
The question than was asked what kind of expression phenotype would be generated upon 
integrating a heterologous promoter into the same chromosomal sites. To answer this, 
targeting was done with a SV40-RFP cassette in which the SV40 promoter drives RFP (pTAR 
SV40 RFP) (Figure 17A). 
 Correctly targeted cells were identified and sorted for lack of GFP expression according to 
the experimental protocol outlined in chapter 3.1.9. Interestingly, different outcome were 
observed in the three cell populations targeted by the SV40-RFP cassette. While for the 
CHOK1 clone 9C the high level of expression of the parental population was maintained, a 
highly heterogeneous expression was observed in clonal populations of clone 17T and clone 
55C (Figure 17B). Both in clone 55C and the PS population of clone 17T, a significant fraction 
of cells could not express RFP although they were successfully targeted.  
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Figure17: A) Schematic representation of Flp recombinase mediated cassette exchange (RMCE) using the 
vectors pTAR SV-40 RFP. B) The clones 17
T
, 9
C
 and 55
C
 were used. Upon RMCE, for each clone, correctly 
targeted cells were isolated by sorting for loss of GFP expression. Sorted cells were evaluated for RFP 
expression by flow cytometry.The upper row of FACs plots in Figure 17B represents the parental state prior to 
targeting and the lower row represents the state after targeting 
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3.1.8d Evaluation of the methylation state of the SV40 promoter upon targeting in high 
expressing sites 
 
The introduction of naked DNA elements in the previous chapters showed different 
expression patterns which suggested that the crosstalk of the expression cassettes with the 
chromosomal environment plays a crucial role in determining the expression from a 
transgene introduced in the genome. However, the question was if the underlying 
epigenetic mechanisms were same or different. In particular, this concerned the 
situation/the case where the introduction of the heterologous promoter lead to silencing or 
heterogeneous expression,. In chapter… it was demonstrated that in the parental these sites 
as such were free from the effect of DNA methylation but showed differential histone marks 
(see Figures 11 and 12 for Cl17 NS and PS, respectively). Thus, it was of interest to 
investigate if methylation sets in after targeting of the SV40 promoter cassette and 
contributes to the partial loss of expression. 
Thus, the non-expressing and expressing cell fraction of SV40 RFP targeted clone 55C and 
clone 17T cells were sorted and subjected to DNA methylation analysis of the SV40 promoter 
according to the protocol outlined in chapter 3.1.4. Interestingly, from the 14 CpGs 
evaluated, none of them was affected by DNA methylation (Figure 18).  
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Figure 18: DNA methylation analysis of silenced fraction of SV40 driven RFP targeted populations from 
Cl17
T
 and Clone 55
C
.Genomic DNA was isolated from the negative sorted populations of HEK293T 
(Cl17) and CHOK1 (Cl55) clones and subjected to bisulfite conversion. The promoter region was 
amplified by PCR and integrated into a cloning vector. Random clones were picked and sequenced. 14 
CpG motifs from the SV40 promoter fragment are shown by circles. Each circle in a line represents a 
CpG dinucleotide. The figure shows the sequences from randomly selected clones reflecting 
independent single cells. Unfilled circle represent non methylated CpG dinucleotides and black filled 
circles represent methylated CpG dinucleotides 
 
 
3.1.9 Summary of results on targeted integration 
 
The evaluation of the expression upon integration of heterologous promoter SV40, 
interestingly, revealed a very interesting expression profile. Staring from the complete loss 
of the complete expression in 293T Cl17 PS  suggested that this site is not good for SV40 
driven transgene expression. However, other site such as in CHO Cl9C showed maintenance 
of parental expression phenotype. Such kinds of sites are rare but are important since these 
might be the sites that can favour transgene expression from different transgenes. CHO 
CL55C represented an intermediate between the two extremes where the integration 
resulted into the clone becoming unstable with a distinct population having lost expression 
transgene, however it still had a population that expressed the transgene. 
Together, the three clones investigated here nicely represent various expression patterns 
namely stable maintenance of expression, stable silencing and heterogeneous expression. 
All the three sites showed good expression of CMV driven transgenes with high and stable 
expression of both GFP and RFP (Figure 15). This not only justified the strategy used for 
screening (lentiviral transduction and sorting for high expression on day10) but also 
suggested that the CMV driven expression might also be used to screen for sites that can 
support strict inducible transgene expression as shown for Cl17 PS (Figure16). This is helpful 
since the inducible expression from the CMV driven Tet promoter can have stochastic 
activation and this might pose problems in screening for good integration sites.  
Another interesting observation that came out is the prospect of locating a site that can be 
used to universally express different transgenes. The Cl9C represented one of the few sites 
that showed uniform and stable transgene expression from both types of promoter. 
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Although, the promoter strength might vary in a particular site but the uniform expression 
was highly promising. The DNA methylation independent silencing of transgene expression 
was quite interesting. On one hand, this suggested that the SV40 can also be silenced in 
DNA methylation independent manner while on the other hand it also suggested that these 
sight are more prone to getting silenced by mechanism that donot involve methylation of 
DNA.  
Overall, this section of the thesis evaluated different integration sites and the transgene 
expression. Most of integrations sites do not have homogeneous expression and are marred 
by some levels of heterogeneity. However, once screened for high expression using a certain 
promoter-transgene combination might result into screening for integration sites that are 
specific for this combination. This is also reflected by the epigenetic pattern that is imbibed 
by the transgene and similar epigenetic might be inherited by other transgenes as long as 
the promoter –integration site are kept the same.  
However, upon integration of a different promoter in the screened site might no longer be 
fit for stable expression.  The expression of transgene from new promoter might be dictated 
by the new kind of crosstalk. 
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3.2 Results Part 2 
 
3.2 Crosstalk between synthetic construct in the Rosa26 locus 
 
The previous chapter described the modulation of the well-known and widely used CMV 
promoter in different integration sites in biotechnologically relevant CHO and HEK293T cell 
lines. A similar situation arises upon genetic modification of stem cells when generating 
transgenic animal models. In this chapter, the focus will be on the crosstalk arising from the 
integration of a Tetracycline inducible promoter (Tet promoter) in the well-characterized 
Rosa26 locus of mice (Soriano et al,). In particular, this focus is laid on the evaluation of the 
RosaGFP mice. 
 
3.2.1Expression analysis of RosaGFP mice 
 
TheRosaGFP transgenic mouse line was previously generated upon integrating a synthetic 
bidirectional Tet (BiTet) promoter cassette into the Rosa26 locus by RMCE (99). For this 
purpose, embryonic stem (ES) cells were used in which the Rosa locus had been modified by 
the heterospecific FRT sites (FRT-WT and FRT-F5)(see Figure 19A). RMCE was used to 
integrate a cassette comprising the BiTet promoter driving GFP and luciferase. This cassette 
also includes the gene for the BiTet transactivation (rtTA) which is expressed from the 
ubiquitously active Rosa 26 promoter upon RMCE (Figure 19B). Thus, this cassette 
comprises all elements required for Dox controlled expression in all tissues in the 
mouse.Therefore in this Rosa GFP transgenic mouse model, administration of Doxycycline 
results in binding of the rtTA to the BiTet promoter, thereby leading to activation of 
transcription from the BiTet promoter. Hence, upon Doxycycline administration ubiquitous 
expression of GFP and luciferase would take place. As a control, the theConL mouse line was 
used. In this line, the luciferase gene is integrated into the Rosa26 locus (Sandhu et al., 
2011).  
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Figure 19: Schematic depiction of the genomic structure of the Rosa26 locus (not to scale) and the 
neighbouring endogenous promoters along with the CpG islands. This locus was made RMCE 
competent by implementation of FRT-WT/FRT-F5 sites as indicated (99)On the level of ES cells, a 
synthetic cassette has been integrated into this locus.The cassette comprises of a synthetic Tet 
promoter (BiTet) driving luciferase and GFP, and rtTA gene which would driven by the Rosa26 
promoter upon targeting). From these ES cells, a transgenic mouse line was generated, designated as 
RosaGFP (Sandhu and Wirth, unpublished) 
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To evaluate gene expression, Rosa-GFP mice were initially kept without Doxycycline and 
were measured via in vivo bioluminescence (see chapter 2.2.10 for the details). Only 
residual basal levels of luciferase expression were determined. This ranged below 2000 
p/s/cm2/sr.To switch the BiTet promoter into transcriptionally active form and induce the 
expression of GFP and luciferase, these mice were then fed with 0.2mg/ml of Doxycycline in 
the drinking water for more than 2 weeks (18 days). These mice were then monitored for 
the luciferase expression via bioluminescence using in vivo IVIS imaging. As a comparison, 
RosaConL mice with constitutive expression of luciferase from the Rosa26 promoter were 
included. 
Figure 20: Luciferase expression inRosaGFP mice: A) BiTet driven expression of luciferase in Rosa-GFP 
mice was quantified using in-vivo IVIS imaging. The expression of luciferase was quantified in mice 
before and after feeding with 0.2 mg/ml Dox in drinking water for 18 days. The control for luciferase 
was constitutively luciferase expressing ConL mice with luciferase under the Rosa26 promoter (99). B) 
The graph shows the luciferasequantification in the two mice groups i) without Dox ii) with Dox (n=6, 
significance was calculated usingMann Whitney test, p=0,0649) 
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Surprisingly, in the induced state the bioluminescence signal was only slightly induced from 
1400(p/s/cm2/sr) to 3879 (p/s/cm2/sr). In contrast, in the Con L mouse a signal of 10E7-10E8 
(p/s/cm2/sr) was detected (see representative pictures in Figure 20A). 
When comparing the expression in individual mice, some amount of mouse to mouse 
variation was observed (Figure 20A and data not shown). However, in none of the mice 
pronounced induction of luciferase expression was observed.Statistical analysis revealed 
that the mice did not show a significant regulation of the luciferase expression in the BiTet 
on(+Dox) and BiTet off (-Dox) state (Figure 20B). 
3.2.2 Partial rescue of the transgene expression upon treatment with Dnmt inhibitors 
 
The lack of expression of the luciferase as measured from bioluminescence in the induced 
RosaGFP transgenic mouse model was in sharp contrast to the high expression of control 
RosaConL mice which had constitutive luciferase expression from the Rosa26 promoter. It 
was hypothesisedthat epigenetic influences could lead to the lack of transgene expression in 
the Rosa26 site. Epigenetic modulation could affect either the BiTet promoter or the Rosa26 
promoter driving the rtTA transactivator.  
In a first analysis it was evaluated if transgene expression is affected by DNA methylation.  
Therefore, the role of DNA methylation in the silencing of Tet driven transgene in the Rosa 
locus was first to be investigated. For this purpose, in this study Azacytidine (Aza) and 
Decitabine (Deci) were used since they specifically impair DNA methyltransferase (Dnmt) 
activity. In order to investigate the possible role of DNA methylation in lack of Tet driven 
transgene expression, the RosaGFPmice were investigated upon treatment with the DNMT 
inhibitors Aza and Deci (0.5mg/ml each, intraperitonally) for two consecutive days in 
presence and absence of Doxycycline (groups 3 and 4 in Figure21). As a control, mice 
without DNMT treatment were analyzed in presence and absence of Doxycycline (groups 1 
and 2 in Figure 20). Since demethylation is restricted to actively proliferating cells, Rosa-GFP 
mice from group 3 and group 4 were additionally treated with 10 µl/gcarbon tetrachloride 
(CCl4) at day 0. CCl4is known to cause liver damage after being metabolized (133), thereby 
inducing proliferation in the liver cells. The overall scheme is summarized in Figure 21A. 
 RESULTS 
73 
 
 
Figure 21: Transgene expression pattern of RosaGFP mice upon treatment with Dnmt inhibiting drugs: 
A) Depiction of experimental procedure with mice being subjected to CCl4(10μl/g) induced liver 
damage on day 0 and consecutive treatments with Azacytidine and Decitabine (0.5mg/ml each) on 
day 1 and day 2 followed by IVIS measurements on day 3. B) The graph shows the average radiance of 
non-induced mice (-Dox), induced mice (+Dox) and uninduced mice with additional treatment of 
Dnmt inhibitors upon CCl4 mediated liver damage(-Dox+CCL4+Azacytidine+Decitabine) and induced 
mice with additional treatment of Dnmt inhibitors upon CCl4 mediated liver damage 
(+Dox+CCL4+Azacytidine+Decitabine) (p=0.02 using Mann Whitney Tet). C) Mice were sacrificed and 
characterized by histology staining of liver tissue sections using an anti-GFP antibody. Representative 
pictures from mice of all the four groups are shown. Scale bar100um, each group had 4 mice (n=4) 
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To confirm the induction of proliferation upon CCL4 mediated liver damage, the sections 
were stained for Ki-67 expression. Ki-67 is a proliferation marker. For this purpose tissue 
sections from liver, spleen and kidney of the 4 mouse groups were used. Indeed, only the 
liver sections of CCL4 treated mice (group3 and group4) showed profound staining for Ki-67 
(data not shown) indicating active proliferating liver tissue. No significant staining was 
observed in the other organs (data not shown) which was expected since liver is the primary 
site of injury post CCL4 treatment.  
The luciferase expression was measured on day 3 (Figure 21B) after the initial CCL4 
treatment via bioluminescence using in vivo IVIS imaging. A significantly increased luciferase 
expression by nearly 100 fold was observed in group 4 (+Dox/+CCL4/+Aza +Deci) in 
comparison to untreated control group mice group 2 (+Dox only) (Figure 21B). 
 
Further to evaluate the expression of GFP, the animals were sacrificed and tissue slides from 
liver were stained with an anti-GFP antibody. No expression was observed in groups 1, 2 and 
3 as well as in control animals treated with CCl4 only (Figure 21C and data not shown). 
However, samples from group 4 showed broad staining of hepatocytes with large number of 
hepatocytes showing positive GFP staining. This indicated that the expression seen after the 
treatment was specific and strongly suggested the prevalence of DNA methylation in the Tet 
driven transgene expression in the Rosa 26 locus. Interestingly, in these conditions not all 
hepatocytes showed transgene expression 
Thus, a partial rescue not only in luciferase expression but also in GFP expression upon 
treatment with azacytidine and Decitabine in mice from group 4 was observed. This 
observation strongly supported the hypothesis of DNA methylation mediated silencing of 
the Tet driven transgene might be occurring in the Rosa locus. Further chapter focused on 
analyzing whether the Tet promoter was silenced leading to loss of transgene expression or 
the Rosa26 promoter was silenced, leading to loss of transactivator expression. 
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3.2.3 DNA methylation pattern of the BiTet promoter in the Rosa26 locus 
 
The RosaGFP mice showed hardly any expression in all organs (Figure 20 and data not 
shown). The treatmentwith Azacytidine and Decitabine resulted in partial rescue of GFP and 
luciferase expression in Rosa-GFP transgenic mice. This strongly suggested the possibility of 
BiTet promoter and Rosa26 promoter being silenced due to methylation of it CpG motifs.  
Firstly, the BiTet promoter was analyzed. It has a high density of CpGs with 5 CpGs each in 
the minimal CMV promoter regions and one CpG in each of the linker DNA connecting the 
seven tetracycline operator repeats, together resulting in 17 CpGs (Figure22A).   
To analyse the methylation status of the Tet promoter DNA samples from liver were taken 
from three individual RosaGFP mice and were subjected to bisulfite treatments per the 
protocol described in chapter3.2.2. A specific primer set was used to amplify the whole 
BiTet promoter. PCR fragments were cloned and a minimum of 8 random clones were 
analysed. After sequencing, the methylated cytosines in the BiTet promoter were 
determined. 
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Figure 22: DNA methylation analysis of the BiTet promoter.  A: depiction of the BiTet promoter. The 
position of the 17 CpG motifs is indicated. B: Genomic DNA was isolated from the liver tissues of three 
Rosa-GFP mice and subjected to the indicated treatments (see Figure 21 for description of the 
treatment). After bisulfite conversion the promoter region was amplified by PCR. The amplified 
product was integrated into a cloning vector. Random clones were picked and sequenced. The 
methylation pattern of three mice per group is depicted. Each circle in a line represents a CpG 
dinucleotide, the complete row of 17 circle represents the BiTet promoter in a single cell. Eight 
promoter fragments per sample are depicted. Unfilled circle represent non methylated CpG 
dinucleotides and black filled circles represent methylated CpG dinucleotides 
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The methylation analysis revealed high levels of methylation both in untreated and 
Doxycycline treated animals (group 1 and group 2 in Figure 20). The three group 1 animals 
showed methylation frequencies of 93-97%, the Doxycycline induced group displayed 91-
94% methylation.  In contrast, the mice subjected to CCL4 and Dnmti treatment overall 
methylation was found to be indeed decreased significantly with 63%, 68% and 65% for the 
three animals. 
Importantly, the treatment with CCl4 + Aza did indeed result in the partial demethylation of 
the BiTet promoter. This suggests that indeed epigenetic silencing is on the basis of the 
BiTet promoter. The results nicely correlate with the observed rescue of luciferase 
expression and the GFP expression (cf. Figure 22). Still, a large number of CpGs remained 
methylated which corresponds to a significant number of non-expressing cells as revealed 
by the histology (Figure 21C). This could be the consequence of limited efficiency of such 
treatments. Alternatively, other factors might also play a role in bringing about silencing of 
BiTet. 
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3.2.4 Endogenous Rosa26 promoter and Thumpd3 promoter remained methylation free 
upon targeting the Tet driven constructs. 
 
Theoretically, lack of expression of the BiTet promoter might have been a consequence of 
silencing of the Rosa26 driven rtTA gene that is required for transcriptional activation of the 
BiTet promoter.The locus harbours two classical CpG island promoters in close proximity, 
namely Rosa26 and Thumpd3 promoter (Figure 23A). The endogenous Rosa26 locus is 
known to show a ubiquitous expression pattern in various developmental stages. High levels 
of polymerase II occupancy and high levels of H3 acetylation were observed for the Rosa26 
promoter upon chromatin immune precipitation (ChIP) in non-modified mouse NIH3T3 cells 
(data not shown). However, different studies suggested the possibility of spreading of the 
DNA methylation which could affect also such an endogenous promoter (134-136):  
according to this study highly methylated sequence can trigger the spread of methylation in 
the neighbouring sequence. Thus, the question arose if thehighly methylatedBiTet promoter 
could trigger the methylation of the endogenous promoters that flank the transgene 
integration site. 
To answer this question, DNA methylation analysis of the endogenous Rosa26 locus was 
performed. Thus, bisulfite treatment of DNA isolated from liver, lung, kidney and spleen of 
RosaGFP mice wasperformed. In this experiment, another method was applied to assess the 
level of methylation. Instead of cloning the PCR amplified fragments, a mass spectrometric 
analysis was performed using Epitypher (Sequenom). In contrast to the analysis of few PCR 
fragments representing individual cells the Epitypher analysis provides quantitative data 
relying on a large number of reads/data points per sample allowing statistical evaluation.  
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Figure 23: DNA methylation analysis of the Rosa26 locus. A) Map of the Rosa26 locus harbouring two 
classical CpG island promoters; the Rosa26 promoter and the Thumpd3 promoter. B) The heat maps 
represent the results of the methylation analysis done on Epitypher. The reference scale is shown 
below. Red represents 0-15%, dark green 50% (0.5) methylation and light green being 100% (1.0) of 
methylation. The various CpG motifs of the two promoters are indicated on the right side of each 
map. Ref1 represents the reference for in vitro methylated fragment with 50% methylation while ref2 
is the 100 percent in vitro methylation reference. Each column represents different CpG from a single 
liver sample from independent mice while each row represents same CpG analysed for different 
samples. 
In contrast to the fully methylated control (Ref 2 in Figure 23 ), the quantitative DNA 
methylation analysis from liver revealed very low levels of overall methylation in both the 
endogenous promoter regions Rosa26 and Thumpd3 (Figure 23B). The results of the analysis 
from other organs such as spleens, lungs, kidney were comparable (data not shown). This 
indicates that the endogenous promoters remain methylation free even if they are flanked 
by a highly methylated BiTet promoter element. Together, these results clearly indicate that 
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the spreading phenomenon as suggested by certain studies (134-136) does not occur in the 
Rosa locus.   
Together, with the results obtained in the previous chapter 3.2.4; this suggests that the high 
levels of methylation are restricted to the transgene with hyper methylated Tet promoter 
not having any affect on the expression of the Rosa26 driven rtTA gene.  
 
3.2.5 Partial rescue of GFP expression upon treatment with Azacytidine and Decitabine in 
the RosaGFP mES cells 
 
In vivo based expression analysis and also the ex vivo histological staining confirmed the role 
of Dnmti in rescuing the transgene expressing. Further the DNA methylation analysis of the 
liver tissues showed high levels of methylation in the BiTet promoter. The partially 
demethylated state obtained upon treatments with Dnmti post CCL4 treatments gave an 
important insight into the role of DNA methylation in silencing the Tet driven transgene 
expression. However, certain questions were still unanswered. This concerned the question 
if methylation was established already on ES cell level or if it was established during 
development. Another question was if DNA methylation was the only factor contributing to 
silencing or if there were other epigenetic mechanisms contributing to silencing.  
To investigate such issues the RosaGFP embryonic stem cell line was used which represents 
the earliest state directly after targeting. To evaluate the expression level, the RosaGFP mES 
cells were kept with (2 µg/ml) Doxycycline for a period of 72 hrs and subjected to flow 
cytometry analysis. Strikingly, the frequency of GFP expressing cells in the presence of Dox 
was only about 1.6%. To evaluate if this low number of GFP expressing cells could be 
rescued with the treatment with Dnmti, the Rosa-GFP mES cells were treated the Rosa-GFP 
mES cells with 0.5ug/ul Azacytidine and Decitabine for 72 hours. The cells were analyzed 
both independently and in combination. Then the cells werereanalysed the GFP expression 
through flow cytometry. Interestingly, the transgene expression in the mES cells increased 
to 6 and 8% upon treatment with Aza and Deci, respectively and nearly 10% following the 
treatment with the combination of both Dnmti (Fig 24). However, a full activation was not 
obtained. This suggests thatthe Dnmti can increase the expressionof the cassette in ES cells. 
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However, it cannot be excluded that the treatment was not fully efficient or that there 
might be other factors that might also contribute towards stabilizing the silencing of the Tet 
promoter apart from DNA methylation. 
 
Figure 24: Treatment of the Rosa-GFP mES cells with Azacytidine (Aza) Decitabine (Deci) at a final 
concentration of 1μM and 0.5 μM respectively for 72 hrs. The graph shows partial rescue of GFP 
expression upon treatment with these inhibitors in a synergistic manner (bars represent three 
replicate per group). 
Still, even without the Dnmti the percentage of GFP positive mES cells did not correspond to 
the lack of expression in the tissue (cf Figure 21).  This suggests that expression is lost during 
development. To evaluate the developmental stage when the BiTet promoter was 
methylated, RosaGFPmES cells were differentiated invitroby formation of hanging drops. 
Interestingly, Tet driven transgene expression was significantly lost upon these early steps 
of differentiation (data not shown). The loss of transgene expression could be attributed to 
high levels of methylation of the Tet promoter right from early stages of differentiation 
(data not shown). 
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3.2.6   Cell to cell heterogeneity in the Tet methylation pattern of RosaGFP ES cells 
 
The presence of both expressing and non-expressing cells in the same cell culture suggests 
cell to cell variability in the activation of the BiTet promoter in ES cells (Figure24). Such 
stochasticity can be due to epigenetically altered chromatin in individual cells which could 
contribute to the heterogeneous phenotype observed. In order to study the heterogeneous 
phenotype in more detail, theinduced RosaGFP mES cells were sorted upon treatment with 
the Dnmti Azacytidine and Decitabine (1μM and 0.5 μMfor 72 hrs). 
 
 
Figure 25: Flow cytometry plot of RosaGFP mES cells upon treatment with Azacytidine (Aza) and 
Decitabine (Deci) and the gating strategy used for sorting. DNA from the two sorted populations was 
isolated and was subjected to bisulfite conversion. Analysis was performed as for Figure 11 
GFP positive Sort(Ps) GFP negative Sort(Ps)
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Interestingly, the methylation analysis of the GFP positive fraction revealed drastic 
reduction of the overall methylation levels to 50% while in the GFP negative fraction nearly 
90% of mCpGs were observed. Together, this indicates a certain correlation between the 
transgene expression and BiTet promoter methylation 
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3.2.7 Evaluation of a CpG free bidirectional Tet promoter in the Rosa26 locus 
 
The DNA methylation of bidirectional Tet promoter was shown to contribute to suppression 
of transgene expression. Though partial rescue was achieved upon treatment with the 
DNMT inhibitors the methylation analysis showed a significant level of methylation even in 
the GFP sorted mES cell population. This strongly suggests that there might be other 
mechanisms responsible for suppressing the Tet driven expression. To prove this, all the 
CpG motifs in the bidirectional Tet promoter were eliminated without changing the CpG 
motif of the coding regions. For this purpose, a modified, CpG free synthetic BiTet promoter 
was synthesized (Figure26) in which all the CpGs were replaced by TG. The promoter was 
cloned into the Rosa-GFP construct, thereby substituting the original BiTet promoter. 
Thereby the vector was obtained with both the GFP and luciferase under the control of the 
CpG free bidirectional Tet promoter.  
First, the activity of the promoter was tested. For this purpose, the construct was 
transfected into HEK293T cells, together with reverse transactivator plasmid (rtTA). Two 
days after transfection, the cells were evaluated for GFP expression. 
 
Figure 26: Depiction of the de novo synthesized CpG free Rosa GFP vector.  CpG free Tet promoter 
was synthesized where the all the CpG motifs were replaced by TG. 
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Figure 27: Expression analysis of GFP driven by normal and CpG free BiTet promoterA) GFP expression 
analysis upon transient co-transfection of CpG free Rosa GFP vector and normal Rosa-GFP vector in 
HEK293T cells along with rtTA. B) Upon integration into the Rosa 26 locus through RMCE, clonal 
population of ES cells were generated and analyzed for expression upon cultivation without and with 
Doxycycline. 
 
Importantly, the CpG free promoter showed nicely regulated expression in the transient 
experimental settings in 293T. The overall expression level was comparable to the classical 
promoter. This indicates that elimination of the CpGs did not compromise the strength or 
inducibility.   
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In order to evaluate the performance of the CpG free promoter in the Rosa26 locus, the 
vector was targeted into the RMCE competent ES cells by Flp mediated RMCE according to 
the previously published protocol (99).It was expected that in these cells expression would 
not be compromised by DNA methylation mediated silencing. Targeted cells were analyzed 
for GFP expression in presence and absence of Doxycycline according to the previously 
described procedure. Strikingly, although all the potentially methylated CpG motifs have 
been eliminated only 7% GFP expressing mES cells were identified in induced state. Thus, a 
significant number of cells did not express the transgene. 
Together this suggests that the Tet driven expression in the Rosa26 locus might not only be 
hindered by DNA methylation but that the BiTet promoter is also affected by other 
epigenetic mechanisms. 
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4 DISCUSSION 
 
Transgenic models have given the researcher a new tool to carry out investigation 
concerning question in basic research. Whether it is model a disease or using a transgenic 
model for drug screening, the overall utility of transgenic models has been immense. Not 
only basic research but also the field of biotech have benefited from development of various 
recombinant models allowing expression of heterologous proteins from recombinant cell 
lines. However the major bottleneck in the transgenesis is the stability of expression of the 
transgene. With single cell analysis now available, the phenotypic heterogeneity in 
expression has now been reported frequently. This variable transgene expression is 
considered to be a result of the crosstalk of the incoming promoter cassette with cis-acting 
elements associated with the chromosomal site of transgene integration (position effect). 
However, the understanding of underlying mechanisms mediating these interactions of 
proximal as well as distal cis and trans acting regulatory elements has remained unclear.  To 
have a mechanistic understanding of the nature of interaction that occurs upon the 
integration of thetransgene in defined chromosomal sites and how the transgene 
expression is modulated more than 100 independent cell clones in two different cell lines 
(CHOK1 and HEK293T) having single copy of hCMV promoter driven transgene were 
analyzed for variability in inter and intraclonal expression phenotype.This approach was 
based on a traditional screening approach where the various integration sites were 
screened for high expression and analysed for the transgene expression.  
The study on CHOK1 and HEK293T cellscould shed light on the epigenetic modulation upon 
transgene integration occurring in two biotechnologically relevant cell lines. The findings of 
histone regulation of the CMV promoter involved in intraclonal variation provide novel 
insights into the nature of epigenetic crosstalk between the incoming cassette and the 
integration site. Unexpectedly, the heterogeneity associated with the hCMV driven 
constructs in the CHO and HEK293T clones was not associated with DNA methylation. In 
contrast, the hCMV promoter was associated with distinct histone modifications causing 
variable transgene expression and transgene silencing. Importantly, upon partially altering 
these histone marks with treatment with epigenetic modifiers like Sodium butyrate and 
Valproic acid, known HDAC inhibitors, transgene expression was partially restored. This 
 DISCUSSION 
88 
 
supports the idea that the histone modifications played a major part in activating or in 
suppressing transgene expression upon cell propagation in CHO and HEK293T cell. 
Targeting of pre-selected chromosomal sites has been proposed to limit the position 
dependent expression of transgenes (137,138). The integration of a transgene in predefined 
sites allows for predictable expression since the effect of the neighbouring chromosomal 
elements are defined and thus the environment of the transgene doesnot change much. 
Thus, in the second approach of this thesis the known open chromatin locus Rosa26 in the 
murine system was targeted with Tetracycline inducible synthetic promoter (Tet) cassettes. 
Targeting was expected to give a predictable and homogenous transgene expression. 
Integration of synthetic constructs adds a new dimension to the already complex interaction 
that occurs when a transgene controlled by natural promoters is integrated in the genomic 
locus. The Tetracycline inducible promoter (Tet promoter system) is one such synthetic 
promoter element that has been designed to yield a controlled transcription of genes under 
it. This Tet promoter comprises of a minimal viral CMV promoter along with fused operator 
sequences from the bacterial operon system to which the transactivators binds and thereby 
activating transcription from the CMV promoter fragment fused to it. Thus, the combination 
of viral and bacterial elements in the Tet system can result in a unique crosstalk when 
integrated in the defined locus. 
However, targeting of the Rosa26 locus with the synthetic cassettes resulted in a highly 
heterogeneous and low expression. The results clearly show that cassettes with Tetracycline 
(Tet) inducible promoter system are highly susceptible to epigenetic silencing by 
mechanisms like DNA methylation in particular.The transgene expression was evaluated 
upon single integration of Tet driven transgene in the Rosa26 locus that was previously 
suggested to support transgene expression(96,97,139). The result of this thesis shows that 
the general expectation that Tet driven transgene work efficiently in these known loci is not 
valid and robust for different experimental settings. The tendency of Tet promoters to get 
methylated and loose expression was shown to be the case in both the Rosa26 as well as 
Col1A1 locus. Interestingly, though the treatment with drugs like Azacytidine and Decitabine 
did lead to reduction in the DNA methylation levels and also lead to the partial recovery of 
the expression of the GFP and luciferase driven by the BiTet promoter, the recovery was not 
obtained in all cells. Rather, a highly heterogeneous cell to cell variation was observed. 
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4.1 Spreading of DNA methylation 
 
The hypothesis of spreading of DNA methylation from a highly methylated foci to nearby 
regions was showed elegantly in a study by Jahner and Jaenish(140) were an integrated 
retroviral elements lead to de novo methylation of chromosomal sites nearby. Further, it 
was proposed by Tucker et al(136) that this spreading of DNA methylation is caused by the 
highly methylated regions that acts like a nucleation centre and triggers the spreading of 
DNA methylation to distal sites. This event is mechanistically driven by recruitment of 
repression complexes at the methylated sites. These complexes then interact with the 
nearby region and alter the chromatin making it more susceptible to DNA methylation 
machinery.  
Thus, to evaluate if such kind of crosstalk also occur in the Rosa locus since the Tet promoter 
being highly methylated (>90% see Figure 22) could act as the nucleation centre triggering 
the methylation of nearby regions, the endogenous neighbouring regions having CpG island 
promoters namely the Rosa26 promoter and Thumpd3 promoter were evaluated for their 
methylation state. However, the Rosa26 and Thumpd3 promoter largely remained 
methylation free. This might be explained by the fact that there might be certain protective 
mechanism that protect these active promoter regions from the effect of nearby 
methylation(134). 
4.2 Screening as a method to identify stable integration sites in cell lines 
and mice 
 
Stable and predictable expression pattern are highly desirable properties in cases of 
generating genetically modified organisms with the use of foreign DNA, be it in the 
development of recombinant cell lines or transgenic animal models today. Till today, the 
biotech industry rely on random integration of the transgene before adopting large scale 
cumbersome screening measure to look for the high producer cells and then going for clonal 
selection. As analyzed in this study, this method not only required large number of clones to 
be screened but is also marred by instability of the clones due to position effects and 
epigenetic silencing.  
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In the first part of the study, the stability of transgene expression in HEK293T cells and 
CHOK1 cells was investigated. Large clone-to clone (interclonal) and cell-to-cell (intraclonal) 
variation was observed. Also, a considerable drop of transgene expression was observed 
during the early phase of establishment of clones. This was more pronounced in CHOK1 
derived cell clones. The clones were established from cells that were initially identified 
according to their high GFP expression. However, a large variance in the GFP expression was 
observed when the clonal populations derived thereof were analysed at passage 2. Of note, 
this was observed both in the HEK293T cells as well as in CHOK1 cell derived clones, 
however to different extents. On the one hand, this variability concerned the clone-to-clone 
variation. This could be explained by the variability in chromosomal integration sites lending 
respective differences in the modulation of transgene expression (position effects). This 
modulation was observed during early phases of cultivation and gave rise to large 
differences of expression (Figure 9 and 10). Interestingly, also cell clones were identified 
with large intraclonal heterogeneity in transgene expression. To identify the underlying 
mechanism, subpopulations displaying high and low/no GFP expressing were isolated, 
respectively, from these heterogeneous clonal populations.  It was observed that while in 
some clones these subpopulations stably maintained their phenotype over passaging, clone 
31T and 42T showed a dynamic (metastable) phenotype with populations shifting between 
the expressing and non-expressing states (Figure 16). In these clones, the expressing and 
non-expressing subpopulations merged upon passaging. Thus, these clones represent a 
metastable state with continuous stochastic alterations in gene expression. This shift in the 
expression was highly interesting and might be explained the effect of transcriptional bursts 
modulating the expression of transgene. Transcriptional burst is a phenomenon where 
multiple transcripts are produced in short span of time due to combined firing of RNA 
polymerase II and the it is followed by a phase of non transcription(141,142). Since the 
lentiviral particles are known to integrate in a semi-random manner, with most of them 
integrating in the transcriptionally active region(141), heterogeneity in transcription of 
transgene could be conveyed by the site of integration (143).    
Another reason for heterogeneity in transgene expression could be the stochastic 
inactivation that has been previously observed for genes located in the vicinity of a 
heterochromatic region. The spreading of these heterochromatin regions have been shown 
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to occur to a different extent and thus comprise a variable length in individual cells leading 
to the position effect variegation (PEV) (144-147). Similarly, transgenes inserted within or in 
the vicinity of heterochromatic regions often become stochastically inactivated (148).  Thus, 
from the screening approach it was evident that most of the integration events occurred at 
sites in the genome that didnot support high expression of the transgene and are might also 
have been marred by possible modulation from the transcriptional burst. Therefore, most 
integration sites lead to large variability in the clonal properties. 
4.3 Predictability of transgene expression upon targeted integration and its 
limitations 
 
Recombinase mediated cassette exchange  was employed on one hand to investigate if an 
expression pattern is re-established on a neutral cassette upon targeted integration of 
plasmid DNA in tagged CHOK1 and HEK293T cells.  
Also, this method (RMCE) was used to answer if a defined, ubiquitously expressing 
integration site could be used to achieve conditional regulated expression from synthetic 
BiTet driven transgenes from pre tagged Rosa26 locus. 
4.3.1 Targeted integration in preselected loci in HEK293T and CHOK1 
 
To achieve this in CHOK1 and HEK293T, a bias-free approach was adopted and the targeted 
clones were sorted for the loss of fluorescent marker (GFP/RFP) that confirms the excision 
of the parental cassette. Importantly, this avoided any selection for expression of a 
resistance marker which might have imposed per se, alterations in the epigenetic pattern of 
the incoming cassette. Interestingly, by re-integration of the epigenetically neutral CMV 
promoter driving RFP as a reporter, the phenotype of the parental cells was re-established. 
This was also true for CMV based inducible Tet promoter driven expression. However, in 
contrast, upon targeting with the SV40 promoter driving the same reporter, the 
predictability in the expression was completely lost. Only one out of three cell clones could 
reproduce the expression status, while the others dropped in expression. Together, this 
indicates a differential influence of a given chromosomal integration site on incoming 
promoters. This might explain the previously reported finding that predictable expression 
upon targeted integration is restricted to the same design of expression cassettes (116,130).  
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4.3.2 Targeted integration in Rosa26 locus 
 
Targeting of pre-selected chromosomal sites has been proposed to overcome position 
dependent expression of heterologous expression (108,117). Indeed, this method allows 
predicting expression of transgenes and thereby facilitates fast and reliable establishment of 
production cell lines (109,115,149). Another alternative to achieve predictable transgene 
expression is to look for loci which support stable expression and reuse them.Since a 
number of loci are already available/known supporting either stable constitutive transgene 
expression (150,151) and/or inducible expression of transgenes (139)(96,152-154) These 
genomic loci have been adapted for site-specific recombination technology that will allow 
the efficient reuse of these genomic loci. These strategies were employed/introduced to 
circumvent the need for doing large scale screens for every new transgene that needs to be 
expressed. With this thesis, the well known Rosa26 locus was targeted with the synthetic 
Tet promoter driven construct and subsequent transgene expression was evaluated. The Tet 
combination with these two loci was expected to show strictly controlled transgene 
expression. Contrary to the expectations, the Tet promoter was found to be highly prone to 
DNA methylation in the Rosa26 locus (Figure 22).The targeting of Rosa26 was expected to 
support transgene expression as it has been previously reported by various studies 
conducted in other laboratories(155). However, contrary to general expectations the 
predictability was compromised even in this case. The expression from the Tet promoter 
driven transgenes was heterogeneous with high mouse to mouse variability (PhD thesis, 
Natascha Kruse 2013 and other data not shown). This kind of variability was not restricted 
to different mouse but was even seen at the cellular levels (see Figure21)(139). These 
findings again emphasise that the settings adopted in screening in different studies with 
different readouts for transgene expression might lead to variable conclusions. However, 
the findings in the current thesis support the highly unstable and variable BiTet driven 
transgene expression in the Rosa26 locus  
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4.4 Epigenetic mechanisms involved intransgene silencing 
 
The role of epigenetic mechanisms like DNA methylation and histone repression has been 
known to play a key role in the silencing of transgenes. Most often the transgene silencing 
has been shown to lead to a loss of transgene expression not only in cell lines based systems 
but also in vivo in mice. These epigenetic processes were known to act together to silence 
the transgene expression (156,157)especially in cases where transgene form tandem 
repeats(158). However the extent to which each of these mechanisms can act individually is 
still not clearly understood.  
 
4.4.1 Evaluation of transgene modulation in HEK293T and CHOK1 cell lines 
 
To identify the epigenetic mechanism underlying the unstable and heterogeneous transgene 
expression in CHO and 293T cell clones, a systematic evaluation was performedto study the 
impact of DNA methylation and histone modifications(Figure12 and 13). The study focused 
on clones with single copy integration events. Thereby, the heterogeneous and unstable 
expression in the selected clones could be attributed to a specific integration site and could 
exclude overlapping effects that would arise from multi-copy integrations. This excluded 
cassette induced silencing which was previously reported to accompany tandem or multi-
copy integrations in defined loci. In this situation unstable transgene expression was 
observed which was independent on the copy-number (158-160). 
Importantly, in the selected clones from HEK293T, the expression status of the clonal 
populations correlated with a specific histone modification pattern. Histone modifications 
have been considered to convey dynamic changes that can be triggered for e.g. by slight 
change in the environment (161,162). Decrease in histone H3 acetylation can lead to 
compaction of the DNA since these acetyl groups are known to neutralize the positive 
charges of histones and thus preventing strong interaction between histone and negatively 
charged phosphate group of DNA (163). Also, markings like H3K27me3 have been known to 
lend a stably silenced phenotype in DNA methylation independent manner. In agreement 
with this, a pronounced enrichment of Histone H3 lysine 4 acetylation (H3k4ac) marks in all 
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the positive sorted populations and the more frequent occurrence of the Histone H3 lysine 
27 trimethylation (H3K27me3) in all the negative sorted populations were observed. The 
surprising factor was the absence of DNA methylation in the clonal populations that lost GFP 
expression stably both in 293T as well as in CHOK1 derived clonal populations (Figure11). 
DNA methylation state of CMV promoter was also evaluated at late passages (Figure11), 
however complete absence of methylation signified the stability of histone mediated 
repression. Also, the presence of other mechanism involved that might contribute to 
stabilize this repression apart from DNA methylation can also not be ruled out.  
4.4.2 Epigenetic influences on Tet promoter in Rosa26 locus 
 
The role of DNA methylation did not significantly contribute to the silencing of CMV driven 
transgene in CHO and HEK293T. However, the contribution of this epigenetic mark was 
significantly more prominent in the Tet driven transgene in the Rosa26 (Figure21 and 22). 
The targeting of transgenes in the open, ubiquitous loci like the Rosa26 was expected to 
give a predictable and homogenous transgene expression. However, the results (Figure22) 
clearly show that cassettes with Tetracycline (Tet) inducible promoter system are highly 
susceptible to epigenetic silencing by mechanisms like DNA methylation in particular. 
Interestingly, there have been already few indications that the Tet promoter is silenced in 
particular sites. It was previously published (164)that the BiTet promoter is susceptible to 
epigenetic modifications. This study was done in random integration settings and focused 
only on the brain tissue. The mechanism that might underlie crosstalk between the 
synthetic Tet driven constructs and defined sites in the chromosomes have largely remained 
out of focus. The current study looked into such kind of crosstalk and the underlying 
mechanism. The transgene expression was evaluated upon single integration of Tet driven 
transgene in the Rosa26 locus that is known to support transgene expression(96,97). The 
Tet promoter, although CMV derived also have parts from bacterial operon system and this 
might be the trigger that makes the Tet promoter susceptible to silencing by getting 
methylated.However the role of the integration site cannot be overlooked. Since the same 
Tet promoter worked very efficiently upon targeting in the 293T CL 17 PS (Figure 18) 
suggests that upon targeting the promoter in the favourable position in the genome, the 
crosstalk can support Tet driven transgene expression. However, the same promoter system 
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in different genomic location can be silenced upon unfavourable crosstalk. This was evident 
in case of Tet promoter upon targeting in the Rosa26. 
4.5 The CMV promoter and its sensitivity towards silencing 
 
The CMV promoter is one of the most commonly used promoters for transgene expression. 
However, inspite of the strong viral activity of the CMV promoter, it has been shown to be 
prone to epigenetic silencing. The role of DNA methylation in the silencing of the CMV 
driven transgene in CHOK1 and HEK293T was found to be non significant (Figure11). This is 
in contrast to the role of DNA methylation in CMV promoter silencing shown in the study by 
(119) et al where they have shown that CMV promoter is preferentially silenced in the mES 
cells. However, with the use of the DNMT knock out cells, the expression was not lost and 
the preferential silencing of CMV didnot take place emphasizing the key role of DNA 
methylation mediated silencing of the CMV promoter. However, this was study focused on 
the silencing of CMV promoter in mES cells in the episomal state and therefore the different 
experimental setting can explain the differences that were observed. 
The role of histone markings on the CMV promoter and its effect on the transgene 
expression was studied in details by Mehta et al (120)where they found histone marks that 
could lead to promoter silencing. In the same study they found bivalent chromatin marks 
with CMV promoter being enriched with both repressive and active marks. These bivalent 
markings were held responsible for CMV promoter being in a state from where it can be 
activated. It is tempting to speculate that the metastable phenotype observed in Cl31T and 
Cl42Tmight also have bivalent chromatin marks that might undergo dynamic changes 
causing switch in the phenotype (Figure12).  
4.6 Potential factors responsible for transgene silencing 
 
The transgene expression in eukaryotic cell has been hindered by silencing of the transgene. 
A number of characteristics have been associated with the transgenic elements that make 
them susceptible to silencing. These are 1) transgenes are integrated in array of tandem 
repeats 2) most of them have base sequences that is not common to eukaryotic 
environment 3) most often they are driven by strong viral promoters making them unusual 
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for the normal eukaryotic environment. These factors singly or in combination might trigger 
the cell to treat these transgenic elements similar to transposons or to retroviral elements 
and thereby might silence them. 
Till date large number of factors has been postulated to trigger transgene silencing. The 
transgenic experiments in generally have involved transfection based approaches that have 
yielded large number of copies integration at a site in a tandem repeat manner. In a study 
by Manuelidis .L .et al(165) it was found that 11 megabase of transgene was inserted in the 
mouse chromosome in tandem repeat array and these repeats were enough to undergo 
heterochromatinization. 
The sequence of transgene inserted might also act as a trigger for the transgene silencing in 
an effect that might be modulated by cis acting factors. Again this might not be exclusive 
from the fact that the multicopy silencing is more common then single copy. These cis acting 
factors might also be related to the CpG content. The CpG content has been shown to play a 
major role especially when present in the transcribed region and also it has been proposed 
that the threshold level of the CpGs that are considered normal exists in the genome 
exceeding which might also act as a trigger for suppression (166). 
The presence of strong viral promoters such as the CMV promoter or viral LTRs are reported 
to be very prone to getting silenced (167).This again can partly be dependent on the 
sequence context. The prokaryotic genome has unmethylated CpG dinucleotideswhereas 
the eukaryotic genome has one-fifth of the CpG dinucleotides are methylated (Ref). These 
can be detected by the cell and can cause silencing as a protective mechanism adapted by 
the cell against the parasitic DNA(167). 
4.7 The potential of epigenetic modifiers (Dnmtinhibitors and HDAC 
inhibitors) to alter chromatin state and recover transgene expression 
 
It has been known that two kind of major epigenetic changes account for loss of transgene 
expression. One is DNA methylation and other is chromatin conformation alteration due to 
histone modification. Transgenes such as lentiviral SIN vectors carrying internal promoters 
such as EF1 alpha, CMV and CBA   have been shown to undergo rapid silencing in the 
proviral state itself (Jin He et al,J V 2005).However, several reports show that the transgene 
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expression is recovered partially upon treatment with DNMT inhibitor azacytidine(168). 
Interestingly, also in case of the Tet promoter, the treatment with drugs like Azacytidine and 
Decitabine did lead to reduction in the DNA methylation levels and also lead to the partial 
recovery of the expression of the GFP and luciferase marker genes driven by Tet. In most 
cases, the DNA methylation leads to recruitment of methyl binding proteins that further 
recruit other modifiers like Histone deacetylases (HDACs). Thus, the rescue mostly is not 
hundred percent upon treatment with DNMTi drugs like Azacytidine. This suggests that 
there might be other mechanisms that might be involved in orchestrating the silencing of 
Tet driven transgenes.Therefore, invariably in most cases the methylation of cytosine is also 
accompanied by modification of histone marks and this is consistent with the observation 
that the treatment with Azacytidine lead to partial recovery and this is lost overtime and cell 
stop responding to Azacytidine. However periodic treatments with combination of these 
drugs have been found to be able to sustain transgene expression (Kong Q, 2011) for a 
period of more than 60 days.  
The HDACi inhibitors can remove HDACs and prevent hypoacetylation that has been known 
to cause compaction of DNA. Inspite of all this literature it was highly interesting that the 
clones characterized in depth did not show any significant contribution of DNA methylation 
(Figure 11). However, the effects from HDAC treatment  did indicate the loss of acetylation 
in the GFP non expressing cells thus suggesting that histone mediated repression  not only 
can occur in the absence of DNA methylation but can also be have stable repression. The 
non-expressing populations of clones 31T and 42T increased transgene expression in 
response to the HDACi; Valproic acid (VPA) and Sodium butyrate (NaB) (Figure13). In 
contrast, non-expressing populations of clone 12T, 17T 54T did not respond to this treatment 
(data not shown). This indicates that these clones are stably silenced (48). 
These results might be explained by bivalent histone markings. In this case two kinds of 
histone marks are present, one being repressive marking and other being active marking. In 
such case the bivalent region is said to be poised and can be reactivated by treatments with 
HDACi inhibitors once the repressive modifications are removed. However in certain regions 
of the genome, these histone repressive markings can be catalysed by different kinds of 
enzymes. Hst1 is a HDAC from class 1 HDAC family that contributes to deacetylation from 
the euchromatin region and is therefore susceptible to HDACi like NaB, TSA and VPA (J R 
 DISCUSSION 
98 
 
Dave, 2003). However, Sir2 belonging to  class III of histone deacetylases, and are known to 
cause deacetylation of heterochromatin regions and these are not susceptible to HDACi like 
VPA, NaB and TSA, therefore once a transgene undergoes heterochromatization the 
reactivation by HDACi treatments can no longer take place.   
4.8 Tetracycline inducible promoter in Rosa26 locus: The Rosa-Tet 
combination 
 
The inducible expression from Tet promoter system has been a revelation on its own making 
possible otherwise difficult experimental settings such as conditional expression of toxic 
compounds and developmentally controlled genes (169-171). The targeted integration of 
Tet promoter in Cl17 of HEK293T confirmed that the Tet system integrated in the single 
copy can give strong regulation and high expression. However, the importance of the 
Rosa26 as an integration site for Tet promoter based transgene expression lies in generation 
of transgenic mice since it is known to express during developmental stages and give a 
uniform expression pattern. The work from Masui et al ( ) developed the Rosa Tet system 
where they successfully targeted the mES cells with Tet promoter in the Rosa26 locus and 
could achieve successfully the regulated expression. This study combined the ubiquitously 
expressing Rosa26 locus with the Tet promoter based system. Although they were 
successful in achieving Tet driven expression, they observed that the strict regulation was 
lost after five passages and also the transgene expression was variable. The study discussed 
the possibility of transgene silencing and suggested that the effect could be the result of 
specific sequences of coding genes integrated under the control of Tet promoter. In the 
present study, affect from a different coding sequence was also analyzed. This was done on 
Rosa T-antigen mouse model in which the BiTet promoter was used to express SV40 T 
antigen (data not shown). There too, both in vitro in mES cells and in vivo, it was found that 
the transgene expression from BiTet was hindered dues to DNA methylation.  
Other studies have been conducted in mice showing the utilization of the Tet promoter 
based system upon targeting in the Rosa 26 locus(138,139,155).  These studies were based 
on expression constructs that were slightly different designs with respect to orientation, 
intervening sequences, and targeted gene. While the Dox dependent expression was 
described in the Rosa locus, work from Strathdee et al (155) suggested that transcriptional 
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interference can cause problems and therefore the Tet promoter based expression depends 
on the orientation of the promoter with respect to endogenous Rosa promoter. This 
conclusion seems to be contradictory to the results shown in this thesis. Indeed, it was 
found that both the bidirectional Tet promoter (BiTet) and the unidirectional Tet promoter 
(in both of the possible orientations) could not give a predictable and uniform expression 
(data not shown and PhD thesis, Natascha Kruse, 2013). This suggests that orientation 
dependency is not the major cause of heterogeneous and unstable Tet driven expression.  
Rather, the differences to the other studies might be explained by different read outs. The 
work from Strathdee et al mainly focused on mES cells and overlooked the epigenetic 
mechanism resulting in the differences in the expression phenotype as is reported in the 
current thesis work. 
 In light of the results presented in the result section (chapters 3.2.1-3.2.3 ), and some of the 
work from other groups discussed above, the general proposition that Tet driven transgene 
expresses efficiently in Rosa26 loci cannot be considered to be valid and robust for different 
experimental settings. The tendency of Tet promoters to get methylated and loose 
expression was shown to be quite significant even in the ubiquitous Rosa26 locus. 
4.9 Procollagen (Col1A1) locus as an alternative to Rosa26? 
 
The problems encountered during expression from the Tet driven transgenes in Rosa26 
locus lead to search for other loci. One such locus was found to be the Col1A1 locus. The 
Procollagen locus (Col1A1) was first targeted in sheep(172)It was shown that this locus was 
able to support transgene expression. This eventually lead to the identification and targeting 
of this locus even in mouse(96). In particular, the site was exploited for targeting the dox 
inducible Tet promoter into the ColA1 locus in mouse ES cells and was able to generate 
mouse which successfully expressed the transgene. Strikingly, inspite of the reported strict 
regulation with uniform expression(96), in the current study it was observed that the Tet 
driven transgene expression was found to be silenced in the mES cells upon differentiation 
(data not shown). The methylation analysis showed high levels of methylation during the 
early differentiation stages upon in vitro differentiation. This is partly in line with another 
recent study from Wan et al, 2013 (173) who showed that the expression from Tet 
promoter was sensitive to epigenetic influences in the Col1A1 locus. They showed that this 
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was related to the exposure to the Doxycycline during the early developmental stages. The 
conclusion from the study was that the Tet promoter can be silenced if the transcription 
from Tet is induced early on in developmental stage. But the silencing can be prevented and 
strict regulation can be achieved if the initial few days during embryonic growth does not 
involve the treatment of Doxycycline. Still, these conclusions are not clear since they imply 
that the chromatin conformation later or in cells might be dependent on initial transcription 
from Tet promoter. This is also contradictory to other results from other studies () where 
initial Dox treatments were held essential to switch on the Tet promoter. 
4.10 CpG free Tet promoter- A potential solution to overcome silencing 
 
With high levels of DNA methylation in the bidirectional Tet promoter, one possible way to 
circumvent the problem of DNA methylation could be to eliminate the CpG motifs present in 
the Tet promoter. Thus, in this study, the cytosines of the CpG motifs were replaced by 
thymine and thereby resulting in the CpG free BiTet promoter element. The promoter 
activity of this modified CpG free version of BiTet was found to work very efficiently and 
confers strict regulation.  Upon targeting this CpG free Tet promoter in the Rosa26 locus, 
the expression was improved, however, the overall expression level was induced only by 
seven folds. This could be due the fact that change in the thymine from cytosine might have 
also affected the topology of this DNA fragment upon integration resulting in condensed 
state. Another explanation could be a potential role and significance of histone mediated 
repression and non CpG DNA methylation(174). 
 
Also, with these results, it might be speculated that these silencing mechanism might act in 
layers with DNA methylation being one of the mechanism that might play a role to initiate 
silencing and might explain the partial rescue upon treatment with the DNMT inhibitors. 
However, the real cause of silencing of the Tet promoter in the Rosa 26 locus might not be 
attributed to a single mechanism but might be accounted by various different factors.  
 
 
 
 
 DISCUSSION 
101 
 
4.11 Challenge to the concept of “Safe Harbors” 
 
The promise of genome engineering with stable integration of functional transgenes for the 
therapeutic purposes has also lead to additional safety concerns upon genetic disruption 
caused due to transgene integration. With the predilection of most of retroviral and 
lentiviral based vectors to integrate near the transcribed genes; the major threat was if such 
an integration event leads to activation of oncogenes. However, with nearly eight percent of 
human genome harbouring retroviral elements that stably integrated in the mammalian 
lineage during evolution(175), the idea that there are sites that can support these elements 
lead to the search for the so-called ‘safe harbor’ in the genome, especially with respect to 
human genome. Theoretically, the “genomic safe harbors (GSH)” would be those sites in the 
genome in which transgene can be integrated without disturbing the activity of endogenous 
genes and thus without having any deleterious consequences (oncogenes activation or 
disruption of tumor suppressor), and yet supporting a high and stable transgene expression. 
Several attempts have been made to define such safe harbor sites by criteria such as a 
minimal distance to standard genes and to tumor promoting genes (176,177). However, 
such definitions do not consider the topology of DNA, the possibility of inter-chromosomal 
crosstalk (178) and also the eventual perturbation induced by the integrated expression 
cassette.  
 
While none of the know sites in human genome fulfils all the criteria of GSH, some sites like 
AAVS1, CCR5 and Rosa26 in humans have been proposed to be close to GSH. However, the 
studies with full validation for these sites in terms of transgene expression, safety to host 
upon integration are lacking(179). Although the integration of transgene in the Rosa26 locus 
did not result in the pathophysiology in with mES cells retaining full pluripotency and giving 
rise to a normal mouse, as shown in the studies. Still the study shows that the Rosa26 locus 
in mouse cannot be considered as a safe harbour given the fact the integrated cassettes (at 
least the Tet promoter cassettes) represent a target of pronounced epigenetic modification. 
In addition it was also shown that the expression in this locus varies depending on the stage 
of development (data not shown). 
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The work discussed in above was aimed to characterize the epigenetic modulation 
underlyingcrosstalk between transgene and integration sites. These understandings will not 
only helps to surpass limitations of transgene silencing but also will greatly increase the 
freedom of designing custom-tailored de novo functional transgenes that yield predictable 
and desirable expression.  
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5 Conclusion 
 
While DNA methylation was the major player in the silencing of the Tetracycline based 
promoter systems in murine models, the heterogeneity associated with the hCMV driven 
constructs in the CHO and HEK293T clones was not associated with DNA methylation. In the 
cell lines, the hCMV promoter was associated with distinct histones modifications causing 
variable transgene expression and transgene silencing. Here, the histone modifications 
played a major part in activating or in suppressing transgene expression upon cell 
propagation in CHO and HEK293T cell. 
The first part of the study looked into the epigenetic modulation among different 
integration sites in two different cell lines. The major focus was on elucidating the nature of 
interaction between integration sites and the integrated transgenes. The presence of 
different kinds of clonal populations was attributed to position effects due to different 
nature of integration sites. However, the intraclonal variation observed in metastable clones   
was found to be correlated with differential histone marks. These might be caused due to 
modulations from transcriptional burst resulting in high cell to cell variability in transgene 
expression.   
The Tetracycline based inducible promoter system was found to be highly susceptible to 
silencing by epigenetic modifications in the second part of the thesis. The surprising aspect 
was the fact that inspite of being targeted in the ubiquitously expressing Rosa26 locus, still 
the BiTet were silenced. The findings in the present study not only undermines the utility of 
Rosa locus for mouse transgenesis incase of development of inducible mouse models but 
also brings up the mechanism that are involved in the unfavourable crosstalk that occurs in 
this locus upon targeting of synthetic BiTet promoter driven constructs. 
It is proposed that while the heterogeneous expression is associated with different 
chromatin states, as conferred by various epigenetic role players (DNA methylation and 
Histone modifications), the stability and extent of the variation in transgene expression may 
largely depend on the nature of crosstalk between the chromosomal integration site and 
the synthetic construct which might be stochastic in nature, with some degree of cell to cell 
variability and involves epigenetic role-plays. 
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6 Outlook 
 
The work described in this thesis contributes to the understanding of the underlying 
crosstalk between transgenes and define integration sites. The CHOKI and HEK293T cell 
clones showed high levels variability in transgene expression and also only few specific sites 
being able to support expression from heterologous promoter in the sites screened for high 
expression using a different promoter element. Thus the sites that initially might have open 
chromatin conformation along with transcriptional activating epigenetic signatures can 
undergo changes upon integration of heterologous promoter element making the site unfit 
for high expression. This understanding can be useful for designing a strategy to screen for 
integration sites and these sites might be promoter specific. 
The implication of silencing of BiTet promoter in the Rosa26 locus has shown that inspite of 
this locus being held as the most reliable locus for mouse transgenesis, this locus is not fit 
for expression of transgene from synthetic BiTet promoter which is heavily marred by 
silencing and epigenetic modulations.  
Thus, more options have to be considered for transgenesis which may include redesigning of 
transgenic cassettes with chromosomal elements like LCRS, insulators that can prevent the 
modulation of transgene expression from the neighbouring regions in the genome. The 
understanding and the characterization of underlying mechanism of the crosstalk in the 
present work will helps to circumvent limitations in transgene expression and greatly 
expands the use of transgenic tools in investigating important questions both in basic 
research and biotech.  
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7 Summary 
 
In an attempt to understand the underlying mechanism of the crosstalk that occurs between 
the transgene and chromosomal locus where the transgene gets integrated, the 
investigation of the epigenetic role play was the focus of the study. The epigenetic 
mechanism(s) were evaluated in CHOK1 and HEK293T cells where inter and intraclonal 
clonal heterogeneity of expression upon single copy transgene integration into random 
chromosomal sites was observed. These variations were reflected by differential histone 
modification pattern. We not only identified clones in which the modifications set in early 
after genetic modification and were stably inherited during cell division but also clones in 
which these modifications were dynamic and occurred stochastically upon extended 
cultivation. Importantly, we could restore a stable expression phenotype by targeting the 
chromosomal loci with a related expression cassette that re-established the favourable 
chromatin status. The investigation was also done to evaluate the suitability of Rosa26 locus 
for synthetic Tet promoter driven transgene expression. Inspite of  the Rosa 26 locus being 
ubiquitously expressing; representing an open chromatin state, the BiTet driven constructs 
didnot shown stable expression in the Rosa26 locus and were heavily modulated by 
epigenetic markings in particular; DNA methylation. 
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9.1 LIST OF ABBREVATIONS 
 
 
Abbreviations Explanations 
µ mikro; 10-6 
Ampr Ampicillin resistance gene 
ATCC American Type Culture Collection 
ATP Adenosine triphosphate 
Aza azacytidine 
BCA bicinchoninic acid 
BiTet bidirectional Tet promoter  
BLI bioluminescent imaging 
bp base pair 
BSA bovine serum albumin 
CCL4 carbon tetrachloride 
CMV cytomegalovirus 
CGI CpG islands 
  
Deci decitabine 
DMEM Dulbecco's modified Eagle's medium 
Dnmt DNA methyltransferase 
Dnmti DNA methyltransferase inhibitor 
DNA deoxyribonucleic acid 
dNTP deoxyribonucleotide triphosphate 
Dox doxycycline 
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DTT dithiothreitol 
eGFP enhanced green fluorescent protein 
eGFP/Neo fusion protein of eGFP und neomycine resistance gene 
et al. et alii 
FACS fluorescence-activated cell sorting 
FCS fetal calf serum 
  
FSC forward scatter 
g gram 
G418 aminoglycoside-2’-deoxystreptine (gentamycin derivative) 
GFP green fluorescent protein 
GOI gene of interest 
h hour(s) 
HDAC Histone deacetylase 
HDACi Histone deacetylase inhibitors 
i.p.  intraperitoneal 
IRES internal ribosomal entry site 
k kilo; 103 
kb 1000 base(s) 
KO knock out 
kV 1000 volt(s) 
l liter(s) 
LTR long terminal repeat 
mES murine embryonic stem cel 
min minute(s) 
ml milliliter(s) 
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mRNA messenger RNA 
NaB sodium butyrate 
Neo neomycinephosphotransferase 
ori origin of replication 
p piko; 10-9 
p53 tumor suppressor protein 53 
pA polyadenylation signal 
PBS phosphate buffer saline 
PCR polymerase chain reaction 
PE R-phycoerythrin 
PGK phosphoglycerate kinase 
RFP red fluorescent protein 
RMCE recombinase mediated cassette exchange 
RNA ribonucleic acid 
RNase ribonuclease 
rpm rounds per minute 
rre Rev responsive element  
RT room temperature 
rtTA reverse transactivator of the tet system 
s second(s) 
SDS sodium dodecyl sulfate 
SIN self inactivating 
SMC smooth muscle cell 
SSC sideward scatter 
SV40 Simian Virus 40 
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Tab. Table 
TAg SV40 Large Tumor Antigen 
TE Trypsin- EDTA 
Tet Tetracycline 
tetO operator sequence of tetracyclin resistance system 
Tet-Off tet dependent expression system 
Tet-On tet dependent expression system 
TetR tetracycline Repressor domain 
Tris trishydroxymethylaminomethane 
tTA transactivator of the tet system 
U unit 
VPA valproic acid 
v/v volume/volume; percent by volume 
w.t. wild type 
w/v weight/volume; percent by weight 
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